|
比利时
(述明或其他司法管辖权
公司或组织) |
| |
3841
(主要标准工业
分类代码编号) |
| |
不适用
(税务局雇主
识别号码) |
|
|
乔纳森·L·克拉维茨(Jonathan L.Kravetz),Esq.
约翰·T·鲁迪(John T.Rudy),Esq. Mintz,Levin,Cohn,Ferris,Glovksy& P.C.波佩奥(Popeo,P.C.) One Financial Center(一座金融中心) 马萨诸塞州波士顿,邮编:02111 (617) 542 6000 |
| |
菲利普·雷梅尔斯(Philippe Remels)
NautaDutilh BV/SRL Chaussée de La Hulpe 120 1000比利时布鲁塞尔 +32 2 566 80 00 |
| |
肖恩·肯尼迪(Shayne Kennedy),Esq.
Latham&Watkins LLP 市中心大道650号 20楼 加利福尼亚州科斯塔梅萨,邮编:92626 (714) 540 1235 |
|
| | ||||||||||||||
须注册的每类证券的名称
|
| | |
建议的最大值
总发行价(1) |
| | |
数量
注册费(2) |
| ||||||
普通股,每股无面值
|
| | | | $ | | | | | | $ | | |
|
关于本招股说明书
|
| | | | II | | |
|
商标
|
| | | | II | | |
|
市场和行业数据
|
| | | | III | | |
|
财务信息展示
|
| | | | III | | |
|
招股说明书摘要
|
| | | | 1 | | |
|
产品
|
| | | | 9 | | |
|
汇总合并财务数据
|
| | | | 10 | | |
|
风险因素
|
| | | | 12 | | |
|
有关前瞻性陈述的特别说明
|
| | | | 66 | | |
|
收益使用情况
|
| | | | 68 | | |
|
股利政策
|
| | | | 69 | | |
|
大写
|
| | | | 70 | | |
|
稀释
|
| | | | 71 | | |
|
管理层对财务状况和经营成果的讨论和分析
|
| | | | 73 | | |
|
业务
|
| | | | 90 | | |
|
管理
|
| | | | 131 | | |
|
主要股东
|
| | | | 147 | | |
|
某些关系和关联方交易
|
| | | | 149 | | |
|
股本和公司章程说明
|
| | | | 151 | | |
|
有资格未来出售的股票
|
| | | | 165 | | |
|
重要的美国联邦收入和比利时税收考虑因素
|
| | | | 167 | | |
|
承销
|
| | | | 183 | | |
|
此次发售的费用
|
| | | | 192 | | |
|
法律事务
|
| | | | 193 | | |
|
专家
|
| | | | 193 | | |
|
责任强制执行
|
| | | | 193 | | |
|
您可以在哪里找到更多信息
|
| | | | 194 | | |
|
合并财务报表索引
|
| | | | F-1 | | |
(单位为千,每股数据除外)
|
| |
截至2013年12月31日的年度
|
| |
截至3月31日
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
2021
|
| |
2020
|
| ||||||||||||||
|
€
|
| |
€
|
| |
€
|
| |
€
|
| ||||||||||||||
收入
|
| | | | 69 | | | | | | — | | | | | | 185 | | | | | | — | | |
销货成本
|
| | | | (30) | | | | | | — | | | | | | (52) | | | | | | — | | |
毛利
|
| | | | 39 | | | | | | — | | | | | | 133 | | | | | | — | | |
一般和行政费用
|
| | | | (7,522) | | | | | | (4,226) | | | | | | (1,818) | | | | | | (1,178) | | |
研发费用
|
| | | | (473) | | | | | | (630) | | | | | | (852) | | | | | | (7) | | |
临床费用
|
| | | | (1,053) | | | | | | (848) | | | | | | (342) | | | | | | (177) | | |
制造费用
|
| | | | (460) | | | | | | (489) | | | | | | (901) | | | | | | (62) | | |
质量保证和监管费用
|
| | | | (227) | | | | | | (227) | | | | | | (325) | | | | | | (25) | | |
专利费及相关费用
|
| | | | (123) | | | | | | (267) | | | | | | (674) | | | | | | (58) | | |
治疗开发收入/(费用)
|
| | | | (1,864) | | | | | | (902) | | | | | | (548) | | | | | | (352) | | |
其他运营费用
|
| | | | 459 | | | | | | (126) | | | | | | 4 | | | | | | (191) | | |
当期营业亏损
|
| | | | (11,224) | | | | | | (7,715) | | | | | | (5,323) | | | | | | (2,050) | | |
财政收入
|
| | | | 62 | | | | | | 71 | | | | | | 4 | | | | | | 19 | | |
财务费用
|
| | | | (990) | | | | | | (740) | | | | | | (325) | | | | | | (336) | | |
税前亏损
|
| | | | (12,152) | | | | | | (8,384) | | | | | | (5,644) | | | | | | (2,367) | | |
赋税
|
| | | | (93) | | | | | | (70) | | | | | | (25) | | | | | | (13) | | |
当期亏损
|
| | | | (12,245) | | | | | | (8,454) | | | | | | (5,669) | | | | | | (2,380) | | |
股东应占亏损
|
| | | | (12,245) | | | | | | (8,454) | | | | | | (5,669) | | | | | | (2,380) | | |
货币换算差异
|
| | | | (58) | | | | | | 168 | | | | | | (70) | | | | | | 272 | | |
当期综合亏损总额(扣除税金)
|
| | | | (12,303) | | | | | | (8,286) | | | | | | (5,739) | | | | | | (2,108) | | |
股东应占亏损
|
| | | | (12,303) | | | | | | (8,286) | | | | | | (5,739) | | | | | | (2,108) | | |
每股基本和摊薄亏损
|
| | | | (0.677) | | | | | | (0.568) | | | | | | (0.256) | | | | | | (0.151) | | |
| | |
截至3月31日
|
| |||||||||
| | |
实际
|
| |
已调整(1)
|
| | |||||
(单位:千)
|
| |
2021
|
| |
2021
|
| | |||||
现金和现金等价物
|
| | | € | 86,207 | | | | | | | ||
总资产
|
| | | | 110,650 | | | | | | | ||
股东应占权益总额
|
| | | | 91,503 | | | | | | | ||
总负债
|
| | | | 19,147 | | | | | | |
| | |
截至2021年3月31日
|
| ||||||
(单位:千)
|
| |
实际
|
| |
作为调整后的
|
| |||
现金和现金等价物
|
| | | € | 86,207 | | | | | |
资本和储备 | | | | | | | | | | |
资本
|
| | | | 3,798 | | | | | |
股票溢价
|
| | | | 150,986 | | | | | |
股份支付准备金
|
| | | | 2,650 | | | | | |
货币换算储备
|
| | | | 79 | | | | | |
留存收益
|
| | | | (66,010) | | | | | |
总股本
|
| | | | 91,503 | | | | | |
非流动债务 | | | | |||||||
安稳
|
| | | | 2,737 | | | | ||
不安全
|
| | | | 7,794 | | | | ||
非流动债务总额
|
| | | | 10,531 | | | | ||
流动债务 | | | | |||||||
安稳
|
| | | | 475 | | | | ||
不安全
|
| | | | 8,141 | | | | ||
总活期债务
|
| | | | 8,616 | | | | ||
债务总额
|
| | | | 19,147 | | | | ||
总市值
|
| | | | 110,650 | | | | | |
| | |
截至2021年3月31日
|
| |||||||||
|
每股普通股
|
| |||||||||||
假设首次公开发行(IPO)价格
|
| | | | | | | | | € | | | |
每股普通股历史有形账面净值
|
| | | € | | | | | | | | | |
每股普通股有形账面净值增加,可归因于参与发售的投资者
|
| | | | | | | | | | | | |
作为发行后每股普通股的调整有形账面净值
|
| | | | | | | | | | | ||
向参与发售的新投资者摊薄为调整后每股普通股有形账面净值
|
| | | | | | | | | € | | | |
| | |
普通股
购得 |
| |
总计
考虑事项 |
| |
平均值
单价 |
| |||||||||||||||||||||
|
数
|
| |
百分比
|
| |
金额
(单位:百万) |
| |
百分比
|
| |
普通
分享 |
| |||||||||||||||||
现有股东
|
| | | | | | | | | | % | | | | | $ | | | | | | % | | | | | $ | | | ||
参与此次发行的投资者
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
总计
|
| | | | | | | | | 100% | | | | | $ | | | | | | 100% | | | | | $ | | | |
| | |
截至三个月
3月31日 |
| |
与去年同期相比
变化 |
| | | | | | | ||||||||||||||||||
(单位:千)
|
| |
2021
|
| |
2020
|
| |
欧元
变化 |
| |
%变化
|
| | | ||||||||||||||||
收入
|
| | | € | 185 | | | | | € | — | | | | | € | 185 | | | | | | — | | | | | ||||
销货成本
|
| | | | (52) | | | | | | — | | | | | | (52) | | | | | | — | | | | | ||||
毛利
|
| | | | 133 | | | | | | — | | | | | | 133 | | | | | | — | | | | | ||||
一般和行政费用
|
| | | | (1,818) | | | | | | (1,178) | | | | | | (640) | | | | | | 54.3% | | | | | ||||
研发费用
|
| | | | (852) | | | | | | (7) | | | | | | (845) | | | | | | * | | | | | ||||
临床费用
|
| | | | (342) | | | | | | (177) | | | | | | (165) | | | | | | 93.2% | | | | | ||||
制造费用
|
| | | | (901) | | | | | | (62) | | | | | | (839) | | | | | | * | | | | | ||||
质量保证和监管费用
|
| | | | (325) | | | | | | (25) | | | | | | (300) | | | | | | * | | | | | ||||
专利费及相关费用
|
| | | | (674) | | | | | | (58) | | | | | | (616) | | | | | | * | | | | | ||||
治疗开发费用
|
| | | | (548) | | | | | | (352) | | | | | | (196) | | | | | | 55.7% | | | | | ||||
其他营业收入/(费用)
|
| | | | 4 | | | | | | (191) | | | | | | 195 | | | | | | (102.1)% | | | | | ||||
当期营业亏损
|
| | | | (5,323) | | | | | | (2,050) | | | | | | (3,273) | | | | | | 159.7% | | | | | ||||
财政收入
|
| | | | 4 | | | | | | 19 | | | | | | (15) | | | | | | (78.9)% | | | | | ||||
财务费用
|
| | | | (325) | | | | | | (336) | | | | | | (11) | | | | | | (3.3)% | | | | | ||||
税前亏损
|
| | | | (5,644) | | | | | | (2,367) | | | | | | (3,277) | | | | | | 138.4% | | | | | ||||
赋税
|
| | | | (25) | | | | | | (13) | | | | | | (12) | | | | | | 92.3% | | | | | ||||
当期亏损
|
| | | | (5,669) | | | | | | (2,380) | | | | | | (3,289) | | | | | | 138.2% | | | | |
| | |
截至年底的年度
12月31日 |
| |
与去年同期相比
变化 |
| ||||||||||||||||||
(单位:千)
|
| |
2020
|
| |
2019
|
| |
欧元零钱
|
| |
%变化
|
| ||||||||||||
收入
|
| | | € | 69 | | | | | € | — | | | | | € | 69 | | | | | | — | | |
销货成本
|
| | | | (30) | | | | | | — | | | | | | (30) | | | | | | — | | |
毛利
|
| | | | 39 | | | | | | — | | | | | | 39 | | | | | | — | | |
一般和行政费用
|
| | | | (7,522) | | | | | | (4,226) | | | | | | (3,296) | | | | | | (78.0)% | | |
研发费用
|
| | | | (473) | | | | | | (630) | | | | | | 157 | | | | | | 24.9% | | |
临床费用
|
| | | | (1,053) | | | | | | (848) | | | | | | (205) | | | | | | (24.2)% | | |
制造费用
|
| | | | (460) | | | | | | (489) | | | | | | 29 | | | | | | 5.9% | | |
质量保证和监管费用
|
| | | | (227) | | | | | | (227) | | | | | | — | | | | | | — | | |
专利费及相关费用
|
| | | | (123) | | | | | | (267) | | | | | | 144 | | | | | | 53.9% | | |
治疗开发费用
|
| | | | (1,864) | | | | | | (902) | | | | | | (962) | | | | | | 106.7% | | |
其他营业收入/(费用)
|
| | | | 459 | | | | | | (126) | | | | | | 585 | | | | | | 464.3% | | |
当期营业亏损
|
| | | | (11,224) | | | | | | (7,715) | | | | | | (3,509) | | | | | | (45.5)% | | |
财政收入
|
| | | | 62 | | | | | | 71 | | | | | | (9) | | | | | | (12.7)% | | |
财务费用
|
| | | | (990) | | | | | | (740) | | | | | | (250) | | | | | | (33.8)% | | |
税前亏损
|
| | |
|
(12,152)
|
| | | | | (8,384) | | | | |
|
(3,768)
|
| | | |
|
(44.9)%
|
| |
赋税
|
| | | | (93) | | | | | | (70) | | | | | | (23) | | | | | | (32.9)% | | |
当期亏损
|
| | | | (12,245) | | | | | | (8,454) | | | | | | (3,791) | | | | | | (44.8)% | | |
(单位:千)
|
| |
合同
预支款 |
| |
预支款
收到 |
| |
金额
已报销 |
| |||||||||
总计 | | | | € | 7,627 | | | | | € | 7,627 | | | | | € | 519 | | |
| | |
截至前三个月
3月31日 |
| | | | |||||||||
(单位:千)
|
| |
2021
|
| |
2020
|
| | ||||||||
用于经营活动的现金净额
|
| | | € | (4,159) | | | | | € | (1,197) | | | | ||
用于投资活动的净现金
|
| | | | (1,775) | | | | | | (1,777) | | | | ||
融资活动中使用/产生的净现金
|
| | | | (104) | | | | | | 24,838 | | | | ||
现金和现金等价物的变动
|
| | |
|
(6,038)
|
| | | |
|
21,874
|
| | | ||
汇率对现金和现金等价物的影响
|
| | | € | (55) | | | | | € | 155 | | | |
(单位:千)
|
| |
截至12月31日的年度
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
运营中使用的净现金
|
| | | € | (7,015) | | | | | € | (5,965) | | |
用于投资活动的净现金
|
| | | | (10,693) | | | | | | (5,795) | | |
融资活动的现金净额
|
| | | | 104,176 | | | | | | 733 | | |
汇率变动的影响
|
| | | | (23) | | | | | | 77 | | |
现金及现金等价物变动
|
| | | € | 86,445 | | | | | € | (10,950) | | |
(单位:千)
|
| |
2020
|
| |
2019
|
| ||||||||||||||||||||||||||||||
|
租赁
负债 |
| |
金融
债务 |
| |
贸易&
其他应付款项 |
| |
租赁
负债 |
| |
金融
债务 |
| |
贸易&
其他应付款项 |
| ||||||||||||||||||||
不到1年
|
| | | € | 560 | | | | | € | 632 | | | | | € | 5,313 | | | | | | 353 | | | | | € | 392 | | | | | € | 3,658 | | |
1个 - 5年
|
| | | | 2,186 | | | | | | 4,987 | | | | | | — | | | | | | 709 | | | | | | 2,871 | | | | | | 547 | | |
5年以上
|
| | | | 895 | | | | | | 4,620 | | | | | | — | | | | | | 38 | | | | | | 11,470 | | | | | | — | | |
总计 | | | | € | 3,640 | | | | | € | 10,239 | | | | | € | 5,313 | | | | | € | 1,100 | | | | | | 14,733 | | | | | | 4,205 | | |
类别
|
| |
AHI范围
|
|
正常范围
|
| | | |
轻度阻塞性睡眠呼吸暂停
|
| | 每小时5-14次活动 | |
中度阻塞性睡眠呼吸暂停低通气综合征
|
| | 每小时15-30次活动 | |
重度阻塞性睡眠呼吸暂停低通气综合征
|
| | 每小时超过30个事件 | |
| | |
人口老龄化
30年 - 69年 |
| |
流行率
中等至- 严重的阻塞性睡眠呼吸暂停综合征 30 - 69Y老年人口 |
| |
百分比
中等至- 严重的阻塞性睡眠呼吸暂停综合征 30 - 69Y老年人口 |
| |||||||||
美国 | | | | | | | | | | | | | | | | | | | |
美国
|
| | | | 163,246,772 | | | | | | 23,678,109 | | | | | | 14.50% | | |
初始目标市场 | | | | | |||||||||||||||
欧洲国家 | | | | | | | | | | | | | | | | | | | |
德国
|
| | | | 43,751,645 | | | | | | 14,393,964 | | | | | | 32.90% | | |
西班牙
|
| | | | 26,158,266 | | | | | | 4,233,728 | | | | | | 16.20% | | |
荷兰
|
| | | | 9,050,266 | | | | | | 2,582,583 | | | | | | 28.50% | | |
比利时
|
| | | | 5,917,763 | | | | | | 931,859 | | | | | | 15.7% | | |
11.瑞士
|
| | | | 4,518,615 | | | | | | 1,654,232 | | | | | | 36.60% | | |
澳大利亚和新西兰 | | | | | | | | | | | | | | | | | | | |
澳大利亚
|
| | | | 12,110,362 | | | | | | 581,348 | | | | | | 4.8% | | |
新西兰
|
| | | | 2,256,063 | | | | | | 68,590 | | | | | | 3.0% | | |
初始目标市场总数 | | | | | |||||||||||||||
总计
|
| | | | 103,762,980 | | | | | | 24,446,304 | | | | | | 23.56% | | |
结果
|
| |
基线(n=22)
|
| |
6个月(n=22)
|
| |
平均
差异(95%CI) |
| |
P值
|
|
AHI,活动/小时
|
| |
23.7 ± (12.2)
|
| |
12.9 ± (10.1)
|
| |
10.8±(14.6至7.0)
|
| | | |
ODI,事件/小时
|
| |
19.1 ± (11.2)
|
| | 9.8 ± (6.9) | | |
9.3±(13.1至5.5)
|
| | | |
FOSQ-10 | | |
15.3 ± (3.3)
|
| | 17.2 ± (3.0) | | | 1.9±(0.4至3.4) | | | 0.0157 | |
ESS | | |
11.0 ± (5.3)*
|
| | 8.0 ± (5.4) | | | 3.0±(5.7至0.8) | | | 0.0113 | |
SaO2
|
| | 5.0 ± (6.0) | | | 2.1 ± (3.0) | | | 2.9±(4.6至1.3) | | | 0.0015 | |
唤醒指数,每小时事件数
|
| |
28.7 ± (11.5)
|
| | 16.0 ± (8.0) | | |
12.7±(16.6至8.9)
|
| | | |
睡眠效率(%)
|
| |
84.0 ± (10.8)
|
| | 87.3 ± (8.9) | | |
3.2±(0-01至6.4)
|
| | 0.0494 | |
6个月后的应答率(谢尔标准)
|
| |
22名患者中有11名(50%)
|
| |
北美
|
| | | |
| |
结果
|
| | |
启迪明星选拔赛
|
| | |
ImThera THN2试验
|
| | ||||||||||||||||||||||||
|
基线
平均值±SD;n |
| | |
6个月期
平均值±SD;n |
| | |
6个月期
平均 变异 |
| | |
12个月
平均值±SD;n |
| | |
12个月
平均 变异 |
| | |
基线
平均值±SD;n |
| | |
6个月期
平均值±SD;n |
| | |
6个月期
平均 变异 |
| | |||||
| | AHI,活动/小时 | | | |
32.0 ± 11.8; 126
|
| | |
19.9 ± 16.8; 125
|
| | |
-37.8%
|
| | |
15.3 ± 16.1;
124 |
| | |
-52.2%
|
| | |
34.9 ± 22.5;
43 |
| | |
25.4 ± 23.1;
43 |
| | |
-27.2%
|
| |
| | ODI,事件/小时 | | | |
28.9 ± 12.0; 126
|
| | |
17.8 ± 16.0; 125
|
| | |
-38.4%
|
| | |
13.9 ± 15.7; 124
|
| | |
-51.9%
|
| | |
32.4 ± 22.3;
43 |
| | |
23.6 ± 22.3;
43 |
| | |
-27.2%
|
| |
| | FOSQ-10 | | | |
14.3 ± 3.2; 126
|
| | |
17.0 ± 3.1; 122
|
| | |
18.9%
|
| | |
17.3 ± 2.9; 124
|
| | |
21.0%
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| |
| | ESS | | | |
11.6 ± 5.0; 126
|
| | |
7.4 ± 4.2; 123
|
| | |
-36.2%
|
| | |
7.0 ± 4.2; 124
|
| | |
-39.7%
|
| | |
12.0 ± 4.8;
43 |
| | |
8.3 ± 4.4;
43 |
| | |
-30.8%
|
| |
| | SaO2 | | | |
8.7 ± 10.2; 126
|
| | |
5.6 ± 10.5; 125
|
| | |
-35.6%
|
| | |
5.9 ± 12.4; 124
|
| | |
-32.2%
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| |
| |
唤醒指数,每小时事件数
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| | |
42.7 ± 19.4;43
|
| | |
31.6 ± 20.3;43
|
| | |
-26.0%
|
| |
| | 睡眠效率(%) | | | |
北美
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| | |
北美
|
| |
| | 6个月后的应答率(谢尔标准) | | | |
北美
|
| | |
北美
|
| | |
43例患者中有15例(34.9%)
|
| |
名字
|
| |
年龄
|
| |
职位
|
|
罗伯特·陶布 | | |
73
|
| | 非执行董事(董事会主席) | |
扬克·迪特默(Janke Dittmer)博士 | | |
43
|
| | 非执行董事(董事会副主席) | |
凯文·拉金 | | |
60
|
| | 非执行董事 | |
唐纳德·德约 | | |
61
|
| | 非执行董事 | |
皮埃尔·吉亚内洛医学博士 | | |
64
|
| | 非执行董事 | |
扬·詹森(Jan Janssen) | | |
55
|
| | 非执行董事 | |
于尔根·汉布雷希特(Jürgen Hambrecht)博士 | | |
74
|
| | 非执行董事 | |
奥利维尔·塔尔曼(Olivier Taelman) | | |
49
|
| | 执行董事(首席执行官) | |
名字
|
| |
年龄
|
| |
职位
|
|
奥利维尔·塔尔曼(Olivier Taelman) | | |
49
|
| | 首席执行官兼执行董事 | |
费边·苏亚雷斯·冈萨雷斯(1) | | |
47
|
| | 首席财务官 | |
| | |
年度固定
费用(欧元) |
| |||
董事长 - 非执行董事
|
| | | | 50,000 | | |
独立董事
|
| | | | 25,000 | | |
非执行董事
|
| | | | 25,000 | | |
审计委员会成员的额外费用
|
| | | | 2,500 | | |
薪酬委员会成员的额外费用
|
| | | | 2,500 | | |
科技委员会委员加收费用
|
| | | | 2,500 | | |
| | |
赚取的费用(欧元)
|
| |||
MINV SA
(Robert Taub的管理公司) |
| | | | 50,000 | | |
罗伯特·陶布
(执行主席至2020年9月21日;非执行主席至2020年9月21日) |
| | | | 27,260 | | |
扬克·迪特默(Janke Dittmer)
(非执行董事) |
| | | | 0 | | |
于尔根·汉布雷希特
(截至2020年9月21日的非执行董事) |
| | | | 8,384 | | |
凯文·拉金
(非执行董事) |
| | | | 8,384 | | |
医疗技术高管有限责任公司
(非执行董事至2020年9月21日)(唐纳德·德约管理公司) |
| | | | 9,025 | | |
唐纳德·德约
(截至2020年9月21日的非执行董事) |
| | | | 11,877 | | |
皮埃尔·贾内洛
(雇员及非执行董事) |
| | | | 90,958 | | |
扬·詹森(Jan Janssen)
(非执行董事) |
| | | | 7,685 | | |
名字
|
| |
授权证奖励
|
| ||||||||||||
|
数量
普通 股票 潜在的 认股权证 |
| |
搜查令
行权价格 按普通人计算 分享 潜在的 认股权证(欧元) |
| |
搜查令
到期日 |
| ||||||||
唐纳德·德约
|
| | | | 27,000 | | | | | | 5.17 | | | |
2021年11月3日
|
|
皮埃尔·贾内洛
|
| | | | 6,000 | | | | | | 5.17 | | | |
2021年12月9日
|
|
凯文·拉金
|
| | | | 27,000 | | | | | | 5.17 | | | |
2021年11月3日
|
|
短期激励计划:年度绩效奖金/年度成功费
|
| |||
主要条文
|
| |
简短描述
|
|
性能周期 | | | 一个日历年 | |
目标奖金 | | | 北美 | |
绩效标准和相应的支付水平 | | |
确定一个或多个绩效标准(目标)。
对于每个绩效标准,确定目标和相应的支付水平:
1.如果达到目标:全额支付 2.如果没有达到目标:不支付 |
|
奖金/成功费的计算 | | | 奖金/成功费总额由与各种绩效标准(如果超过一个)相关的支出水平之和组成。 | |
支付方式 | | | 现金付款 一次性支付100%奖金/成功费 |
|
长期激励计划:股票期权计划 | | |||
主要条文 | | | 简要说明 | |
报价频率 | | | 没有预设频率 | |
性能周期 | | | 北美 | |
提供的股票期权的目标数量 | | | 北美 | |
行权价格 | | | 认股权发售日的标的股份价值 | |
运动期 | | |
1.2020年前发行的股票期权计划:自股票期权要约之日起五年
2、2020年发布的股票期权计划:自股票期权发行之日起十年
|
|
绩效标准和相应的产品级别 | | | 北美 | |
短期激励计划:年度绩效奖金/年度成功费
|
| |||
主要条文
|
| |
简短描述
|
|
已发行股票期权数量的计算
|
| | 北美 | |
归属 | | | 分三部分归属: 已发售股票期权的1/3在发售时归属 已发售股票期权的1/3在发售一周年时授予 已发售股票期权的1/3在发售两周年时授予 |
|
留着 | | | 北美 | |
| | |
补偿
(€) |
| |||
基本工资
|
| | | | 262,538 | | |
绩效奖金
|
| | | | 40,000 | | |
养老金缴费
|
| | | | 19,860 | | |
公司用车
|
| | | | 11,632 | | |
医疗保险缴费
|
| | | | 1,903 | | |
退出价值(欧元)
|
| |
赔偿金支付
(以退出值的%为单位,不包括增值税) |
| |||
|
| | | | 0% | | |
≥ 65,000,000
|
| | | | 0.35% | | |
≥ 300,000,000
|
| | | | 0.50% | | |
名字
|
| |
授权证奖励
|
| ||||||||||||
|
数量
普通 股票 潜在的 认股权证 |
| |
搜查令
行权价格 (€) |
| |
搜查令
到期日 |
| ||||||||
奥利维尔·塔尔曼(Olivier Taelman)
|
| | | | 500 | | | | | | 11.93 | | | |
2024年12月23日
|
|
| | | | | 133,000 | | | | | | 6.52 | | | | 2024年7月29日 | |
| | | | | 16,500 | | | | | | 11.93 | | | | 2025年4月7日 | |
| | | | | 320,000 | | | | | | 11.94 | | | |
2030年2月21日
|
|
费边·苏亚雷斯·冈萨雷斯(1)
|
| | | | 25,000 | | | | | | 5.17 | | | | 2022年6月13日 | |
|
姓名或名称
权证计划 |
| |
数量
认股权证 已发布 |
| |
数量
认股权证 已经失效了, 练习 或者没有 更长 可用 申请拨款 |
| |
数量
认股权证 杰出的 |
| |
发行
日期 |
| |
期满
日期 |
| |
锻炼
价格 搜查令 (€) |
| |
数
和类型 股票 可发行的 按员工持股计划 搜查令 |
| |
集料
数 和类型 股票 可发行的 在 锻炼…… 杰出的 认股权证 |
|
|
2013年份额
激励 平面图 |
| |
640
|
| |
499
|
| |
141
|
| |
05/03/2013
12/23/2014 |
| |
05/03/2023
12/23/2024 |
| |
2,585.51(1)
5,966.59(2) |
| |
500
普通 股票 |
| |
70,500
普通 股票 |
|
|
2016
认股权证 平面图 |
| |
1,500
|
| |
1,065
|
| |
435
|
| |
11/03/2016
|
| |
11/03/2026
|
| |
2,585.32(1)
|
| |
500
普通 股票 |
| |
217,500
普通 股票 |
|
|
2018
认股权证 平面图 |
| |
525
|
| |
206
|
| |
319
|
| |
12/12/2018
|
| |
12/12/2028
|
| |
3,259.91(3)
5,966.59(2) |
| |
500
普通 股票 |
| |
159,500
普通 共享%s |
|
|
2020
认股权证 平面图 |
| |
550,000
|
| | | | |
550,000
|
| |
02/21/2020
|
| |
02/21/2030
|
| |
11.94
|
| |
1个普通
分享 |
| |
550,000
普通 股票 |
|
| | | | | | | | | | | | | | | | | | | | | |
总计
|
| |
997,500
普通 股票 |
|
实益拥有人姓名或名称
|
| |
数量
普通股 实益拥有 |
| |
普通股百分比
实益拥有 |
| |||||||||
|
在此之前
供奉 |
| |
之后
供奉 |
| |||||||||||
3%或更大股东: | | | | | | | | | | | | | | | | |
Cochlear Investments Pty Ltd(1)
|
| | | | 3,947,617 | | | | | | 17.86% | | | | | |
与Gilde Healthcare有关联的实体(2)
|
| | | | 3,153,822 | | | | | | 14.27% | | | | | |
罗伯特·陶布(3)
|
| | | | 2,817,470 | | | | | | 12.74% | | | | | |
合伙企业(4)
|
| | | | 2,503,500 | | | | | | 11.32% | | | | | |
于尔根·汉布雷希特(5)
|
| | | | 1,047,029 | | | | | | 4.74% | | | | | |
ResMed Inc.(6)
|
| | | | 794,235 | | | | | | 3.59% | | | | | |
执行干事和董事: | | | | | | | | | | | | | | | | |
罗伯特·陶布(3)
|
| | | | 2,817,470 | | | | | | 12.74% | | | | | |
扬克·迪特默(Janke Dittmer)
|
| | | | — | | | | | | — | | | | | |
凯文·拉金(7)
|
| | | | 117,940 | | | | | | * | | | | | |
唐纳德·德约(8)
|
| | | | 45,000 | | | | | | * | | | | | |
皮埃尔·贾内洛(9)
|
| | | | 6,000 | | | | | | * | | | | | |
扬·詹森(Jan Janssen)
|
| | | | — | | | | | | — | | | | | |
于尔根·汉布雷希特(5)
|
| | | | 1,047,029 | | | | | | 4.74% | | | | | |
奥利维尔·塔尔曼(10)
|
| | | | 470,000 | | | | | | 2.08% | | | | | |
法比安·苏亚雷斯·冈萨雷斯(11岁)
|
| | | | 42,883 | | | | | | * | | | | | |
所有现任董事和执行管理层作为一个整体
(9人)(12人) |
| | | | 4,546,322 | | | | | | 20.52% | | | | | |
|
日期
|
| |
交易记录
|
| |
增加
(减少) 份额的百分比 资本(欧元) |
| |
数
的股份 已发布 |
| |
班级
股票 已发布 |
| |
发行
单价 共享/ 面值 每股(欧元, 四舍五入) |
| |
结果
分享 资本(欧元) |
| |
现有股份
|
|
|
6/29/2016
|
| |
增资(1)
|
| |
719,224.50
|
| |
7,032
|
| |
优先B股
|
| |
2,585.32 /
102.28 |
| |
2,004,255.29
|
| |
总数:19336
7637共同 股票 4,061优先考虑 A股 首选7638个 B股 |
|
|
10/05/2018
|
| |
增资(2)
|
| |
159,014.44
|
| |
1,534
|
| |
首选B2
股票 |
| |
3,259.91 /
103.66 |
| |
2,163,269.73
|
| |
总数:20870
7637共同 股票 4,061优先考虑 A股 首选7638个 B股 首选1,534个 B2股 |
|
|
11/07/2018
|
| |
增资
|
| |
318,028.88
|
| |
3,068
|
| |
首选B2
股票 |
| |
3,259.91 /
103.66 |
| |
2,481,296.61
|
| |
总数:23980
7637共同 股票 4,061优先考虑 A股 首选7638个 B股 首选4602个 B2股 |
|
|
2/21/2020
|
| |
分享
整固 (如下所述) |
| |
北美
|
| |
北美
|
| |
北美
|
| |
北美
|
| |
2,481,296.61
|
| |
29,758
普通股 |
|
|
2/21/2020
|
| |
资本
增加(作为 进一步描述 (见下图) |
| |
435,372
|
| |
4,200
|
| |
普通股
|
| |
5,966.59 /
103.66 |
| |
2,916,670.61
|
| |
33,958
普通股 |
|
|
2/21/2020
|
| |
股份拆分
有一定比例的 第500份:1份(截至 如下所述) |
| |
北美
|
| |
北美
|
| |
普通股
|
| |
北美
|
| |
2,916,670.61
|
| |
16,979,000
普通股 |
|
|
9/07/2020
|
| |
演练
员工持股认股权证 |
| |
7,645.10
|
| |
44,500
|
| |
普通股
|
| |
5.17 / 0.1718
|
| |
2,924,315.71
|
| |
17,023,500
普通股 |
|
|
9/21/2020
|
| |
增资
|
| |
755,981.68
|
| |
4,400,359
|
| |
普通股
|
| |
17 / 0.1718
|
| |
3,680,297.39
|
| |
21,423,859
普通股 |
|
|
9/29/2020
|
| |
增资
|
| |
111,712.95
|
| |
650,250
|
| |
普通股
|
| |
17 / 0.1718
|
| |
3,792,010.34
|
| |
22,074,109
普通股 |
|
|
10/28/2020
|
| |
演练
员工持股认股权证 |
| |
4,037.30
|
| |
23,500
|
| |
普通股
|
| |
5.17 / 0.1718
|
| |
3,796,047.64
|
| |
22,097,609
普通股 |
|
|
2/22/2021
|
| |
演练
员工持股认股权证 |
| |
1,718.00
|
| |
10,000
|
| |
普通股
|
| |
5.17 / 0.1718
|
| |
3,797,765.64
|
| |
22,107,609
普通股 |
|
承销商
|
| |
股份数量
|
| |||
派珀·桑德勒公司(Piper Sandler&Co.)
|
| | | | | | |
Stifel,Nicolaus&Company,Inc.
|
| | | | | | |
康托·菲茨杰拉德公司(Cantor Fitzgerald&Co.)
|
| | | | | | |
Bank Degroof Petercam SA/NV
|
| | | | | | |
总计
|
| | | | | | |
| | |
每股
|
| |
没有选项
|
| |
带选项
|
| |||||||||
公开发行价
|
| | | $ | | | | | $ | | | | | $ | | | |||
承保折扣和佣金
|
| | | $ | | | | | $ | | | | | $ | | | |||
扣除费用前的收益,给我们
|
| | | $ | | | | | $ | | | | | $ | | | |
费用
|
| |
金额
|
| |||
证券交易委员会注册费
|
| | | $ | * | | |
纳斯达克首次上市手续费
|
| | | | * | | |
FINRA备案费用
|
| | | | * | | |
印刷费
|
| | | | * | | |
律师费及开支
|
| | | | * | | |
会计费用和费用
|
| | | | * | | |
杂项费用
|
| | | | * | | |
总计
|
| | | | * | | |
| 截至2020年12月31日和2019年12月31日的经审计综合财务报表 | | | | | | | |
|
独立注册会计师事务所报告
|
| | | | F-2 | | |
|
合并资产负债表
|
| | | | F-3 | | |
|
合并损失表和其他全面损失表
|
| | | | F-4 | | |
|
合并权益变动表
|
| | | | F-5 | | |
|
现金流量合并报表
|
| | | | F-6 | | |
|
合并财务报表附注
|
| | | | F-7 | | |
|
截至2021年3月31日的未经审计简明合并中期财务报表以及截至2021年3月31日和2020年3月31日的三个月期间
|
| | | | | | |
|
中期合并资产负债表
|
| | | | F-46 | | |
|
中期合并损失表和其他全面损失表
|
| | | | F-47 | | |
|
中期合并权益变动表
|
| | | | F-48 | | |
|
现金流量中期合并报表
|
| | | | F-49 | | |
|
截至2021年3月31日的三个月未经审计简明合并财务报表附注
|
| | | | F-50 | | |
| | |
截至12月31日
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
资产 | | | | | | | | | | | | | |
非流动资产 | | | | | | | | | | | | | |
财产、厂房和设备
|
| | | € | 713 | | | | | € | 322 | | |
无形资产
|
| | | | 15,853 | | | | | | 5,734 | | |
使用权资产
|
| | | | 3,283 | | | | | | 1,066 | | |
递延税项资产
|
| | | | 32 | | | | | | 21 | | |
其他长期应收账款
|
| | | | 91 | | | | | | 78 | | |
| | | | € | 19,972 | | | | | € | 7,221 | | |
流动资产 | | | | | | | | | | | | | |
库存
|
| | | | 55 | | | | | | — | | |
其他应收账款
|
| | | | 1,644 | | | | | | 2,108 | | |
其他流动资产
|
| | | | 109 | | | | | | 11 | | |
现金和现金等价物
|
| | | | 92,300 | | | | | | 5,855 | | |
| | | | € | 94,108 | | | | | € | 7,974 | | |
总资产
|
| | | € | 114,080 | | | | | € | 15,195 | | |
权益和负债 | | | | | | | | | | | | | |
资本和储备 | | | | | | | | | | | | | |
普通股
|
| | | | 3,796 | | | | | | 1,122 | | |
优先股
|
| | | | — | | | | | | 1,359 | | |
股票溢价
|
| | | | 150,936 | | | | | | 47,668 | | |
股份支付准备金
|
| | | | 2,650 | | | | | | 420 | | |
货币换算储备
|
| | | | 149 | | | | | | 207 | | |
留存收益
|
| | | | (60,341) | | | | | | (48,415) | | |
股东应占权益总额
|
| | | € | 97,190 | | | | | € | 2,361 | | |
负债 | | | | | | | | | | | | | |
非流动负债 | | | | | | | | | | | | | |
金融债
|
| | | | 7,607 | | | | | | 7,146 | | |
租赁责任
|
| | | | 2,844 | | | | | | 735 | | |
养老金负债
|
| | | | 37 | | | | | | 30 | | |
其他应付款
|
| | | | — | | | | | | 547 | | |
| | | | € | 10,488 | | | | | € | 8,458 | | |
流动负债 | | | | | | | | | | | | | |
金融债
|
| | | | 616 | | | | | | 378 | | |
租赁责任
|
| | | | 473 | | | | | | 340 | | |
贸易应付款
|
| | | | 1,190 | | | | | | 1,385 | | |
其他应付款
|
| | | | 4,123 | | | | | | 2,273 | | |
| | | | € | 6,402 | | | | | € | 4,376 | | |
总负债
|
| | | € | 16,890 | | | | | € | 12,834 | | |
权益和负债总额
|
| | | € | 114,080 | | | | | € | 15,195 | | |
| | |
截至年底的年度
12月31日 |
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
收入
|
| | | € | 69 | | | | | € | — | | |
销货成本
|
| | | | (30) | | | | | | — | | |
毛利
|
| | | € | 39 | | | | | € | — | | |
一般和行政费用
|
| | | | (7,522) | | | | | | (4,226) | | |
研发费用
|
| | | | (473) | | | | | | (630) | | |
临床费用
|
| | | | (1,053) | | | | | | (848) | | |
制造费用
|
| | | | (460) | | | | | | (489) | | |
质量保证和监管费用
|
| | | | (227) | | | | | | (227) | | |
专利费及相关费用
|
| | | | (123) | | | | | | (267) | | |
治疗开发费用
|
| | | | (1,864) | | | | | | (902) | | |
其他营业收入/(费用)
|
| | | | 459 | | | | | | (126) | | |
当期营业亏损
|
| | | € | (11,224) | | | | | € | (7,715) | | |
财政收入
|
| | | | 62 | | | | | | 71 | | |
财务费用
|
| | | | (990) | | | | | | (740) | | |
税前亏损
|
| | | € | (12,152) | | | | | € | (8,384) | | |
所得税
|
| | | | (93) | | | | | | (70) | | |
当期亏损
|
| | | € | (12,245) | | | | | € | (8,454) | | |
其他综合损失 | | | | | | | | | | | | | |
随后可能重新分类为损益(税后净额)的项目 | | | | | | | | | | | | | |
货币换算差异
|
| | | | (58) | | | | | | 168 | | |
本年度扣除税项后的综合亏损总额
|
| | | € | (12,303) | | | | | € | (8,286) | | |
股东应占亏损
|
| | | € | (12,303) | | | | | € | (8,286) | | |
每股基本亏损
|
| | | € | (0.677) | | | | | € | (0.568) | | |
稀释每股亏损
|
| | | € | (0.677) | | | | | € | (0.568) | | |
| | |
可归因于母公司的所有者
|
| |||||||||||||||||||||||||||||||||||||||
| | |
普普通通
股票 |
| |
择优
股票 |
| |
分享
补价 |
| |
基于共享的
付款 保留 |
| |
货币
翻译 保留 |
| |
留用
收益 |
| |
总计
|
| |||||||||||||||||||||
2019年1月1日的余额
|
| | | € | 1,122 | | | | | € | 1,359 | | | | | € | 47,668 | | | | | € | 80 | | | | | € | 39 | | | | | € | (39,967) | | | | | € | 10,301 | | |
全年亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (8,454) | | | | | | (8,454) | | |
的其他全面收入
年 |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 168 | | | | | | — | | | | | | 168 | | |
本年度综合收益/(亏损)总额
|
| | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | | € | 168 | | | | | € | (8,454) | | | | | € | (8,286) | | |
股权结算股份支付
|
| | | | — | | | | | | — | | | | | | — | | | | | | 340 | | | | | | — | | | | | | 6 | | | | | | 346 | | |
2019年12月31日的余额
|
| | | € | 1,122 | | | | | € | 1,359 | | | | | € | 47,668 | | | | | € | 420 | | | | | € | 207 | | | | | € | (48,415) | | | | | € | 2,361 | | |
2020年1月1日的余额
|
| | | € | 1,122 | | | | | € | 1,359 | | | | | € | 47,668 | | | | | € | 420 | | | | | € | 207 | | | | | € | (48,415) | | | | | € | 2,361 | | |
全年亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (12,245) | | | | | | (12,245) | | |
本年度其他全面亏损
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | (58) | | | | | | | | | | | | (58) | | |
本年度综合亏损总额
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | € | (58) | | | | | € | (12,245) | | | | | € | (12,303) | | |
股权结算股份支付
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,230 | | | | | | — | | | | | | 319 | | | | | | 2,549 | | |
优先股转换为普通股
股票 |
| | | | 1,359 | | | | | | (1,359) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | |
|
—
|
| |
发行股票换取现金
|
| | | | 1,304 | | | | | | — | | | | | | 108,857 | | | | | | — | | | | | | — | | | | | | — | | | | | | 110,161 | | |
可转换可转换贷款
|
| | | | 11 | | | | | | — | | | | | | 989 | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,000 | | |
交易成本
|
| | | | — | | | | | | — | | | | | | (6,578) | | | | | | — | | | | | | — | | | | | | — | | | | | | (6,578) | | |
与直接在权益中确认的公司所有者的交易总额
|
| | | € | 2,674 | | | | | | (1,359) | | | | | € | 103,268 | | | | | € | 2,230 | | | | | | — | | | | | € | 319 | | | | | € | 107,132 | | |
2020年12月31日的余额
|
| | | € | 3,796 | | | | | | — | | | | | € | 150,936 | | | | | € | 2,650 | | | | | € | 149 | | | | | € | (60,341) | | | | | € | 97,190 | | |
| | |
截至年底的年度
12月31日 |
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
经营活动的现金流 | | | | | | | | | | | | | |
本年度税前亏损
|
| | | € | (12,152) | | | | | € | (8,384) | | |
对以下各项进行调整: | | | | | | | | | | | | | |
财政收入
|
| | | | (62) | | | | | | (71) | | |
财务费用
|
| | | | 990 | | | | | | 740 | | |
财产、厂房和设备以及使用权资产的折旧和减值
|
| | | | 620 | | | | | | 433 | | |
股份支付交易费用
|
| | | | 2,549 | | | | | | 346 | | |
养老金相关费用
|
| | | | 7 | | | | | | 30 | | |
其他非现金项目
|
| | | | (134) | | | | | | 70 | | |
营运资金变动前产生的现金
|
| | | € | (8,182) | | | | | € | (6,836) | | |
营运资金变动: | | | | | | | | | | | | | |
库存增加
|
| | | | (55) | | | | | | — | | |
其他应收账款减少/(增加)
|
| | | | 365 | | | | | | (1,385) | | |
贸易和其他应付款项的增加
|
| | | | 1,109 | | | | | | 2,342 | | |
运营变化产生的现金
|
| | | € | (6,763) | | | | | € | (5,879) | | |
收到的利息
|
| | | | 3 | | | | | | 8 | | |
支付的利息
|
| | | | (151) | | | | | | (33) | | |
已缴所得税
|
| | | | (104) | | | | | | (61) | | |
用于经营活动的现金净额
|
| | | € | (7,015) | | | | | € | (5,965) | | |
投资活动的现金流 | | | | | | | | | | | | | |
购置物业、厂房及设备
|
| | | | (562) | | | | | | (51) | | |
无形资产资本化
|
| | | | (10,118) | | | | | | (5,734) | | |
增加长期存款
|
| | | | (13) | | | | | | (10) | | |
用于投资活动的净现金
|
| | | € | (10,693) | | | | | € | (5,795) | | |
融资活动的现金流 | | | | | | | | | | | | | |
支付租赁负债的本金部分
|
| | | | (479) | | | | | | (341) | | |
偿还其他贷款
|
| | | | (63) | | | | | | (82) | | |
收到的可收回现金预付款
|
| | | | 190 | | | | | | 1,196 | | |
偿还可收回的现金预付款
|
| | | | (55) | | | | | | (40) | | |
可转换贷款收益
|
| | | | 1,000 | | | | | | — | | |
股票发行收益,扣除交易成本
|
| | | | 103,583 | | | | | | — | | |
融资活动产生的现金净额
|
| | | € | 104,176 | | | | | € | 733 | | |
现金和现金等价物的变动
|
| | | € | 86,468 | | | | | € | (11,027) | | |
汇率对现金和现金等价物的影响
|
| | | | (23) | | | | | | 77 | | |
1月1日的现金和现金等价物
|
| | | € | 5,855 | | | | | € | 16,805 | | |
12月31日的现金和现金等价物
|
| | | € | 92,300 | | | | | € | 5,855 | | |
|
IT设备
|
| | 3年 | |
|
家具和办公设备
|
| | 5到15年 | |
|
实验室设备
|
| | 15年 | |
|
租赁权的改进
|
| | 租期较短,租期为10年 | |
| | |
2020年费率
|
| |
2019年费率
|
| ||||||||||||||||||
货币
|
| |
结业
|
| |
平均值
|
| |
结业
|
| |
平均值
|
| ||||||||||||
新谢斯
|
| | | | 3.92758 | | | | | | 3.92330 | | | | | | 3.87700 | | | | | | 3.99220 | | |
澳元
|
| | | | 1.58636 | | | | | | 1.65548 | | | | | | 1.60102 | | | | | | 1.61057 | | |
美元
|
| | | | 1.22239 | | | | | | 1.15189 | | | | | | — | | | | | | — | | |
| | |
国外的变化
汇率,汇率 |
| |
对亏损的影响(税前)
|
| |
对税前权益的影响
|
| |||||||||||||||||||||||||||||||||
|
新谢斯
|
| |
美元
|
| |
澳元
|
| |
新谢斯
|
| |
美元
|
| |
澳元
|
| ||||||||||||||||||||||||||
2020
|
| | | | 5% | | | | | | 12 | | | | | | -4 | | | | | | 55 | | | | | | 83 | | | | | | -7 | | | | | | 208 | | |
| | | | | -5% | | | | | | -12 | | | | | | 4 | | | | | | -61 | | | | | | -91 | | | | | | 8 | | | | | | -230 | | |
2019
|
| | | | 5% | | | | | | 11 | | | | | | — | | | | | | 39 | | | | | | 71 | | | | | | — | | | | | | 127 | | |
| | | | | -5% | | | | | | -11 | | | | | | — | | | | | | -43 | | | | | | -77 | | | | | | — | | | | | | -141 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||||||||||||||||||||||||||
|
租赁
负债 |
| |
金融
债务 |
| |
贸易&
其他 应付 |
| |
租赁
负债 |
| |
金融
债务 |
| |
贸易&
其他 应付 |
| ||||||||||||||||||||
不到1年
|
| | | | 560 | | | | | | 632 | | | | | | 5,313 | | | | | | 353 | | | | | | 392 | | | | | | 3,658 | | |
1-5岁
|
| | | | 2,185 | | | | | | 4,987 | | | | | | — | | | | | | 709 | | | | | | 2,871 | | | | | | 547 | | |
5年以上
|
| | | | 895 | | | | | | 4,620 | | | | | | — | | | | | | 38 | | | | | | 11,470 | | | | | | — | | |
共计
|
| | | | 3,640 | | | | | | 10,239 | | | | | | 5,313 | | | | | | 1,100 | | | | | | 14,733 | | | | | | 4,205 | | |
(单位:000欧元)
|
| |
账面价值
|
| |
公允价值
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
2020
|
| |
2019
|
| ||||||||||||||
金融资产 | | | | | | | | | | | | | | | | | | | | | | | | | |
其他长期应收账款(三级)
|
| | | | 91 | | | | | | 78 | | | | | | 91 | | | | | | 78 | | |
贸易应收账款和其他应收账款(第3级)
|
| | | | 1,644 | | | | | | 2,107 | | | | | | 1,644 | | | | | | 2,107 | | |
其他流动资产(3级)
|
| | | | 109 | | | | | | 11 | | | | | | 109 | | | | | | 11 | | |
现金和现金等价物(一级)
|
| | | | 92,300 | | | | | | 5,855 | | | | | | 92,300 | | | | | | 5,855 | | |
金融负债 | | | | | | | | | | | | | | | | | | | | | | | | | |
金融债务(三级)
|
| | | | 313 | | | | | | 376 | | | | | | 250 | | | | | | 321 | | |
租赁责任(3级)
|
| | | | 3,317 | | | | | | 1,075 | | | | | | 3,317 | | | | | | 1,075 | | |
可收回现金垫款(3级)
|
| | | | 7,910 | | | | | | 7,148 | | | | | | 7,910 | | | | | | 7,148 | | |
贸易和其他应付款(第3层)
|
| | | | 5,313 | | | | | | 4,205 | | | | | | 5,313 | | | | | | 4,205 | | |
(单位:000欧元)
|
| |
家具和
办公室 装备 |
| |
租赁权
改进 |
| |
实验室
装备 |
| |
总计
|
| ||||||||||||
总值 | | | | | | | | | | | | | | | | | | | | | | | | | |
期初总值
|
| | | | 439 | | | | | | 190 | | | | | | 133 | | | | |
|
762
|
| |
加法
|
| | | | 48 | | | | |
|
—
|
| | | | | 3 | | | | | | 51 | | |
2019年12月31日的毛值
|
| | | | 487 | | | | | | 190 | | | | | | 136 | | | | | | 813 | | |
加法
|
| | | | 178 | | | | | | 358 | | | | | | 26 | | | | | | 562 | | |
2020年12月31日的总价值
|
| | | | 665 | | | | | | 548 | | | | | | 162 | | | | | | 1,375 | | |
折旧 | | | | | | | | | | | | | | | | | | | | | | | | | |
期初累计折旧
|
| | | | (283) | | | | | | (72) | | | | | | (37) | | | | | | (392) | | |
折旧费
|
| | | | (64) | | | | | | (24) | | | | | | (12) | | | | | | (100) | | |
2019年12月31日折旧
|
| | |
|
(347)
|
| | | |
|
(96)
|
| | | |
|
(49)
|
| | | | | (492) | | |
折旧费
|
| | | | (83) | | | | | | (74) | | | | | | (12) | | | | | | (169) | | |
2020年12月31日折旧
|
| | | | (430) | | | | | | (170) | | | | | | (61) | | | | | | (661) | | |
开盘汇差
|
| | | | (3) | | | | | | 2 | | | | | | 2 | | | | | | 1 | | |
汇兑差额
|
| | | | (1) | | | | | | — | | | | | | — | | | | | | (1) | | |
2020年12月31日汇兑差额
|
| | | | (4) | | | | | | 2 | | | | | | 2 | | | | | | — | | |
截至2019年12月31日的账面净值
|
| | | | 137 | | | | | | 96 | | | | | | 89 | | | | | | 322 | | |
2020年12月31日的账面净值
|
| | | | 231 | | | | | | 380 | | | | | | 103 | | | | | | 713 | | |
(单位:000欧元)
|
| |
发展
成本 |
| |
专利和
执照 |
| |
总计
|
| |||||||||
成本 | | | | | | | | | | | | | | | | | | | |
期初总值
|
| | | | — | | | | | | — | | | | | | — | | |
加法
|
| | | | 5,311 | | | | | | 335 | | | | | | 5,646 | | |
2019年12月31日的毛值
|
| | | | 5,311 | | | | | | 335 | | | | | | 5,646 | | |
加法
|
| | | | 9,874 | | | | | | 256 | | | | | | 10,130 | | |
2020年12月31日的总价值
|
| | | | 15,185 | | | | | | 591 | | | | | | 15,776 | | |
摊销 | | | | | | | | | | | | | | | | | | | |
期初摊销
|
| | | | — | | | | | | — | | | | | | — | | |
摊销
|
| | | | — | | | | | | — | | | | | | — | | |
2019年12月31日摊销
|
| | | | — | | | | | | — | | | | | | — | | |
摊销
|
| | | | — | | | | | | — | | | | | | — | | |
2020年12月31日摊销
|
| | | | — | | | | | | — | | | | | | — | | |
开盘汇差
|
| | | | 88 | | | | | | — | | | | | | 88 | | |
汇兑差额
|
| | | | (11) | | | | | | — | | | | | | (11) | | |
2020年12月31日汇兑差额
|
| | |
|
77
|
| | | | | — | | | | |
|
77
|
| |
截至2019年12月31日的账面净值
|
| | | | 5,399 | | | | | | 335 | | | | | | 5,734 | | |
2020年12月31日的账面净值
|
| | | | 15,262 | | | | | | 591 | | | | | | 15,853 | | |
(单位:000欧元)
|
| |
建房
|
| |
马达
车辆 |
| |
总计
|
| |||||||||
总值 | | | | | | | | | | | | | | | | | | | |
截至2019年1月1日
|
| | | | 1,131 | | | | | | 192 | | | | | | 1,323 | | |
添加
|
| | | | — | | | | | | — | | | | | | — | | |
2019年12月31日的毛值
|
| | | | 1,131 | | | | | | 192 | | | | | | 1,323 | | |
添加
|
| | | | 3,194 | | | | | | 233 | | | | | | 3,427 | | |
处置
|
| | | | (1,207) | | | | | | (23) | | | | | | (1,230) | | |
2020年12月31日的总价值
|
| | | | 3,117 | | | | | | 402 | | | | | | 3,519 | | |
折旧 | | | | | | | | | | | | | | | | | | | |
截至2019年1月1日
|
| | | | — | | | | | | — | | | | | | — | | |
当年折旧
|
| | | | (281) | | | | | | (52) | | | | | | (333) | | |
2019年12月31日折旧
|
| | | | (281) | | | | | | (52) | | | | | | (333) | | |
当年折旧
|
| | | | (383) | | | | | | (68) | | | | | | (451) | | |
处置
|
| | | | 470 | | | | | | 11 | | | | | | 481 | | |
2020年12月31日折旧
|
| | | | (194) | | | | | | (109) | | | | | | (303) | | |
期初汇差
|
| | | | 76 | | | | | | — | | | | | | 76 | | |
汇兑差额
|
| | | | (9) | | | | | | — | | | | | | (9) | | |
2020年12月31日汇兑差额
|
| | | | 67 | | | | | | — | | | | | | 67 | | |
截至2019年12月31日的账面净值
|
| | | | 926 | | | | | | 140 | | | | | | 1,066 | | |
截至2020年12月31日的账面净值
|
| | | | 2,990 | | | | | | 293 | | | | | | 3,283 | | |
(单位:000欧元)
|
| | | | | | |
截至2019年1月1日-采用国际财务报告准则第16号
|
| | | | 1,323 | | |
添加
|
| | | | — | | |
利息增值
|
| | | | 17 | | |
付款
|
| | | | (341) | | |
汇兑差额
|
| | | | 76 | | |
截至2019年12月31日的账面净值
|
| | | | 1,075 | | |
添加
|
| | | | 3,427 | | |
处置
|
| | | | (743) | | |
利息增值
|
| | | | 47 | | |
付款
|
| | | | (479) | | |
汇兑差额
|
| | | | (10) | | |
截至2020年12月31日的账面净值
|
| | | | 3,317 | | |
非电流
|
| | | | 735 | | |
当前
|
| | | | 340 | | |
截至2019年12月31日的账面净值
|
| | | | 1,075 | | |
非电流
|
| | | | 2,844 | | |
当前
|
| | | | 473 | | |
截至2020年12月31日的账面净值
|
| | | | 3,317 | | |
(单位:000欧元)
|
| |
31/12/2020
|
| |
31/12/2019
|
| ||||||
使用权资产折旧费用
|
| | | | 451 | | | | | | 333 | | |
租赁负债的利息费用
|
| | | | 47 | | | | | | 17 | | |
租金开支(附注0)
|
| | | | 89 | | | | | | 115 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
可收回预付现金应收账款
|
| | | | — | | | | | | 1,100 | | |
研发奖励应收账款(澳大利亚)
|
| | | | 951 | | | | | | 495 | | |
增值税应收账款
|
| | | | 607 | | | | | | 153 | | |
当期应收税金
|
| | | | (3) | | | | | | 30 | | |
其他
|
| | | | 89 | | | | | | 330 | | |
其他应收账款合计
|
| | | | 1,644 | | | | | | 2,108 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
短期存款
|
| | | | 28 | | | | | | 28 | | |
三个月定期存款
|
| | | | 6 | | | | | | 363 | | |
经常账户
|
| | | | 92,266 | | | | | | 5,463 | | |
零用钱
|
| | | | — | | | | | | 1 | | |
现金和现金等价物合计
|
| | | | 92,300 | | | | | | 5,855 | | |
(除另有注明外,股份数目(1))
|
| |
普普通通
股票 |
| |
择优
股票 |
| |
总计
股票 |
| |
面值
(欧元) |
| |
分享
资本 |
| |
分享
补价 |
| ||||||||||||||||||
2019年1月1日(根据2019年股票拆分进行调整
2020) |
| | | | 6,728,500 | | | | | | 8,150,000 | | | | | | 14,879,000 | | | | | | 0.17 | | | | | | 2,481 | | | | | | 47,668 | | |
2019年12月31日(根据股票拆分进行调整
2020年) |
| | | | 6,728,500 | | | | | | 8,150,000 | | | | | | 14,879,000 | | | | | | 0.17 | | | | | | 2,481 | | | | | | 47,668 | | |
2020年2月21日-优先股转换为普通股
|
| | | | 8,150,000 | | | | | | (8,150,000) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
2020年2月21日-增资
|
| | | | 2,100,000 | | | | | | — | | | | | | 2,100,000 | | | | | | 0.21 | | | | | | 436 | | | | | | 24,624 | | |
2020年9月7日-行使权证
|
| | | | 44,500 | | | | | | — | | | | | | 44,500 | | | | | | 0.17 | | | | | | 8 | | | | | | 222 | | |
2020年9月21日-IPO
|
| | | | 4,335,000 | | | | | | — | | | | | | 4,335,000 | | | | | | 0.17 | | | | | | 745 | | | | | | 72,950 | | |
2020年9月21日-可转换贷款
|
| | | | 65,359 | | | | | | — | | | | | | 65,359 | | | | | | 0.17 | | | | | | 11 | | | | | | 989 | | |
2020年9月29日-行使权证
|
| | | | 650,250 | | | | | | — | | | | | | 650,250 | | | | | | 0.17 | | | | | | 112 | | | | | | 10,943 | | |
2020年10月28日-锻炼
认股权证 |
| | | | 23,500 | | | | | | — | | | | | | 23,500 | | | | | | 0.17 | | | | | | 4 | | | | | | 117 | | |
2020年12月31日(根据股票拆分进行调整
2020年) |
| | | | 22,097,609 | | | | | | — | | | | | | 22,097,609 | | | | | | 0.17 | | | | | | 3,796 | | | | | | 157,514 | | |
(股份拆分后)认股权证有权跨越所有计划的股份数目
|
| |
2020
|
| |
2019
|
| ||||||
截至1月1日未偿还债务
|
| | | | 1,143,500 | | | | | | 1,012,000 | | |
授与
|
| | | | 567,000 | | | | | | 246,000 | | |
没收/取消
|
| | | | (635,000) | | | | | | (114,500) | | |
练习
|
| | | | (68,000) | | | | | | 0 | | |
截至12月31日未偿还债务
|
| | | | 1,007,500 | | | | | | 1,143,500 | | |
可于12月31日行使
|
| | | | 1,007,500 | | | | | | 968,503 | | |
2013年计划的认股权证数量(股份拆分后)
|
| |
2020
|
| |
2019
|
| ||||||
截至1月1日未偿还债务
|
| | | | 208,000 | | | | | | 269,500 | | |
授与
|
| | | | 500 | | | | | | 0 | | |
没收/取消
|
| | | | (83,500) | | | | | | (61,500) | | |
练习
|
| | | | (44,500) | | | | | | 0 | | |
截至12月31日未偿还债务
|
| | | | 80,500 | | | | | | 208,000 | | |
可于12月31日行使
|
| | | | 80,500 | | | | | | 208,000 | | |
2016年计划认股权证的股数(股份拆分后)
|
| |
2020
|
| |
2019
|
| ||||||
截至1月1日未偿还债务
|
| | | | 742,500 | | | | | | 742,500 | | |
授与
|
| | | | 0 | | | | | | 0 | | |
没收/取消
|
| | | | (501,500) | | | | | | 0 | | |
练习
|
| | | | (23,500) | | | | | | 0 | | |
截至12月31日未偿还债务
|
| | | | 217,500 | | | | | | 742,500 | | |
可于12月31日行使
|
| | | | 217,500 | | | | | | 695,500 | | |
2018年计划的认股权证数量(股份拆分后)
|
| |
2020
|
| |
2019
|
| ||||||
截至1月1日未偿还债务
|
| | | | 193,000 | | | | | | 0 | | |
授与
|
| | | | 16,500 | | | | | | 246,000 | | |
没收/取消
|
| | | | (50,000) | | | | | | (53,000) | | |
练习
|
| | | | 0 | | | | | | 0 | | |
截至12月31日未偿还债务
|
| | | | 159,500 | | | | | | 193,000 | | |
可于12月31日行使
|
| | | | 159,500 | | | | | | 65,000 | | |
2020年计划认股权证数量
|
| |
2020
|
| |||
截至1月1日未偿还债务
|
| | | | 0 | | |
授与
|
| | | | 550,000 | | |
没收/取消
|
| | | | 0 | | |
练习
|
| | | | 0 | | |
截至12月31日未偿还债务
|
| | | | 550,000 | | |
可于12月31日行使
|
| | | | 550,000 | | |
总计
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
12月31日的可行使权证
|
| | | | 550,915 | | | | | | 1,940 | | | | | | 1,807 | | |
相当于12月31日可行使权证的股份
|
| | | | 1,007,500 | | | | | | 1,143,500 | | | | | | 1,012,000 | | |
每股加权平均行权价
|
| | | | 9.17 | | | | | | 5.26 | | | | | | 5.17 | | |
| | |
2016年计划
(赠款2018) |
| |
2018年计划
(GRANT 2019) |
| |
2013年计划
(GRANT 2020) |
| |
2018年计划
(GRANT 2020) |
| |
2020年计划
(GRANT 2020) |
| |||||||||||||||
返还股利
|
| | | | 0% | | | | | | 0% | | | | | | 0% | | | | | | 0% | | | | | | 0% | | |
预期波动率
|
| | | | 66.92% | | | | | | 56.32% | | | | | | 56.32% | | | | | | 56.32% | | | | | | 56.32% | | |
无风险利率
|
| | | | 0.35% | | | | | | -0.20% | | | | | | -0.20% | | | | | | -0.20% | | | | | | -0.20% | | |
预期寿命
|
| | | | 3 | | | | | | 3 | | | | | | 3 | | | | | | 3 | | | | | | 3 | | |
行权价格
|
| | | | 5.17 | | | | | | 6.52 | | | | | | 11.94 | | | | | | 11.94 | | | | | | 11.94 | | |
股票价格
|
| | | | 1.09 | | | | | | 10.24 | | | | | | 10.20 | | | | | | 10.20 | | | | | | 10.20 | | |
公允价值
|
| | | | 0.10 | | | | | | 5.30 | | | | | | 3.31 | | | | | | 3.31 | | | | | | 3.31 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
可收回现金预付款-非流动
|
| | | | 7,419 | | | | | | 6,874 | | |
可收回现金预付款--当期
|
| | | | 491 | | | | | | 274 | | |
可收回现金预付款总额
|
| | | | 7,910 | | | | | | 7,148 | | |
其他贷款--非流动贷款
|
| | | | 188 | | | | | | 272 | | |
其他贷款-流动贷款
|
| | | | 125 | | | | | | 104 | | |
其他贷款总额
|
| | | | 313 | | | | | | 376 | | |
非电流
|
| | | | 7,607 | | | | | | 7,146 | | |
当前
|
| | | | 616 | | | | | | 378 | | |
金融债务总额
|
| | | | 8,223 | | | | | | 7,524 | | |
(单位:000欧元)
|
| |
合同
预支款 |
| |
预支款
收到 |
| |
金额
已报销 |
| |||||||||
睡眠呼吸暂停设备(6472)
|
| | | | 1,600 | | | | | | 1,600 | | | | | | 420 | | |
第一篇文章(6839)
|
| | | | 2,160 | | | | | | 2,160 | | | | | | 84 | | |
临床试验(6840)
|
| | | | 2,400 | | | | | | 2,400 | | | | |
|
—
|
| |
激活芯片改进(7388)
|
| | | | 1,467 | | | | | | 1,467 | | | | | | 15 | | |
总计 | | | | | 7,627 | | | | | | 7,627 | | | | | | 519 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
收到的可收回现金预付款
|
| | | | 7,627 | | | | | | 7,437 | | |
报销金额(2倍)
|
| | | | 15,254 | | | | | | 14,874 | | |
年终报销金额(含利息)
|
| | | | (582) | | | | | | (517) | | |
可收回现金预付款总额(未贴现)
|
| | | | 14,672 | | | | | | 14,357 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
合同6472
|
| | | | 1,421 | | | | | | 1,296 | | |
合约6839
|
| | | | 2,214 | | | | | | 2,115 | | |
合约6840
|
| | | | 2,592 | | | | | | 2,232 | | |
合约7388
|
| | | | 1,683 | | | | | | 1,505 | | |
可收回现金预付款总额
|
| | | | 7,910 | | | | | | 7,148 | | |
非电流
|
| | | | 7,419 | | | | | | 6,874 | | |
当前
|
| | | | 491 | | | | | | 274 | | |
可收回现金预付款总额
|
| | | | 7,910 | | | | | | 7,148 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
截至1月1日
|
| | | | 7,148 | | | | | | 5,357 | | |
收到的预付款
|
| | | | 190 | | | | | | 1,196 | | |
已报销垫款(不含利息)
|
| | | | (55) | | | | | | (40) | | |
初始测量和重新测量
|
| | | | (145) | | | | | | 60 | | |
贴现影响
|
| | | | 772 | | | | | | 575 | | |
截至12月31日
|
| | |
|
7,910
|
| | | |
|
7,148
|
| |
截至2020年底的负债公允价值(单位:欧元)
|
| |
收入预测的变动
|
| |||||||||||||||
更改贴现率*
|
| | | | -25% | | | | | | 0% | | | | | | 25% | | |
-25%
|
| | | | 8,787 | | | | | | 9,099 | | | | | | 9,281 | | |
0%
|
| | | | 7,567 | | | | | | 7,910 | | | | | | 8,114 | | |
+25%
|
| | | | 6,566 | | | | | | 6,922 | | | | | | 7,138 | | |
(0000029欧元)
|
| |
2020
|
| |
2019
|
| ||||||
应付款
|
| | | | 815 | | | | | | 1,174 | | |
应收到的发票
|
| | | | 375 | | | | | | 211 | | |
贸易应付款总额
|
| | | | 1,190 | | | | | | 1,385 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
其他非流动应付款合计
|
| | | | — | | | | | | 547 | | |
假日应计工资
|
| | | | 376 | | | | | | 243 | | |
薪金
|
| | | | 382 | | | | | | 381 | | |
应计费用
|
| | | | 1,244 | | | | | | 687 | | |
其他
|
| | | | 2,121 | | | | | | 962 | | |
其他当前应付款合计
|
| | | | 4,123 | | | | | | 2,273 | | |
(单位:000欧元)
|
| |
2020
|
| |||
购买商品和服务
|
| | | | 85 | | |
库存移动
|
| | | | (55) | | |
销货成本
|
| | | | 30 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
员工成本
|
| | | | 3,015 | | | | | | 1,327 | | |
咨询费和承包费
|
| | | | 2,883 | | | | | | 1,733 | | |
律师费
|
| | | | 201 | | | | | | 42 | | |
租金
|
| | | | 89 | | | | | | 115 | | |
设施
|
| | | | 116 | | | | | | 67 | | |
折旧及摊销费用
|
| | | | 599 | | | | | | 415 | | |
信通技术
|
| | | | 234 | | | | | | 151 | | |
旅行
|
| | | | 134 | | | | | | 186 | | |
其他费用
|
| | | | 251 | | | | | | 190 | | |
一般和行政费用合计
|
| | | | 7,522 | | | | | | 4,226 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
员工成本
|
| | | | 1,304 | | | | | | 1,252 | | |
咨询费和承包费
|
| | | | — | | | | | | 11 | | |
外包开发项目
|
| | | | 1,717 | | | | | | 1,054 | | |
折旧及摊销费用
|
| | | | 20 | | | | | | 16 | | |
旅行
|
| | | | 4 | | | | | | 33 | | |
其他
|
| | | | 21 | | | | | | 9 | | |
资本化成本
|
| | | | (2,593) | | | | | | (1,745) | | |
研发费用总额
|
| | | | 473 | | | | | | 630 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
员工成本
|
| | | | 1,531 | | | | | | 921 | | |
咨询费和承包费
|
| | | | 748 | | | | | | 474 | | |
临床活动
|
| | | | 1,731 | | | | | | 1,190 | | |
旅行
|
| | | | 51 | | | | | | 182 | | |
其他
|
| | | | 255 | | | | | | 114 | | |
资本化成本
|
| | | | (3,263) | | | | | | (2,033) | | |
临床总费用
|
| | |
|
1,053
|
| | | | | 848 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
员工成本
|
| | | | 1,211 | | | | | | 613 | | |
咨询费和承包费
|
| | | | — | | | | | | — | | |
制造业
|
| | | | 2,427 | | | | | | 1,071 | | |
旅行
|
| | | | 25 | | | | | | 41 | | |
其他
|
| | | | 139 | | | | | | 87 | | |
资本化成本
|
| | | | (3,342) | | | | | | (1,323) | | |
总制造费用
|
| | | | 460 | | | | | | 489 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
植入式刺激器
|
| | | | 1,660 | | | | | | 686 | | |
激活芯片
|
| | | | 228 | | | | | | 67 | | |
一次性贴片
|
| | | | 102 | | | | | | 113 | | |
体外刺激器
|
| | | | 69 | | | | | | 37 | | |
其他
|
| | | | 368 | | | | | | 168 | | |
资本化成本
|
| | | | (2,254) | | | | | | (800) | | |
总计 | | | |
|
173
|
| | | | | 271 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
员工成本
|
| | | | 641 | | | | | | 353 | | |
咨询费和承包费
|
| | | | 291 | | | | | | 400 | | |
QA&法规
|
| | | | 542 | | | | | | 148 | | |
旅行
|
| | | | — | | | | | | 27 | | |
资本化成本
|
| | | | (1,247) | | | | | | (701) | | |
总质量保证和规章制度费用
|
| | | | 227 | | | | | | 227 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
可收回现金预付款 | | | | | | | | | | | | | |
-初始测量和重新测量
|
| | | | 147 | | | | | | (61) | | |
研发奖励(澳大利亚)
|
| | | | 1,000 | | | | | | 425 | | |
R&D激励的资本化
|
| | | | (573) | | | | | | (493) | | |
其他收入/(支出)
|
| | | | (115) | | | | | | 3 | | |
其他营业收入/(费用)合计
|
| | | | 459 | | | | | | (126) | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
薪金
|
| | | | 4,577 | | | | | | 3,625 | | |
社会收费
|
| | | | 562 | | | | | | 518 | | |
附带福利
|
| | | | 104 | | | | | | 153 | | |
固定缴款计划
|
| | | | 249 | | | | | | 258 | | |
假日工资
|
| | | | 273 | | | | | | 99 | | |
股份支付(见附注13)
|
| | | | 2,548 | | | | | | 346 | | |
其他
|
| | | | 138 | | | | | | 127 | | |
员工福利总额
|
| | | | 8,451 | | | | | | 5,126 | | |
一般和行政费用
|
| | | | 3,015 | | | | | | 1,327 | | |
研发成本
|
| | | | 1,304 | | | | | | 1,252 | | |
临床费用
|
| | | | 1,531 | | | | | | 921 | | |
运营和制造费用
|
| | | | 1,211 | | | | | | 613 | | |
QA费用
|
| | | | 641 | | | | | | 353 | | |
其他费用(治疗开发、专利等)
|
| | | | 749 | | | | | | 660 | | |
员工福利总额
|
| | | | 8,451 | | | | | | 5,126 | | |
| | |
截至12月31日,
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
一般事务和行政事务
|
| | | | 9 | | | | | | 5.8 | | |
知识产权与商标
|
| | | | — | | | | | | 1.0 | | |
研究与发展
|
| | | | 10.8 | | | | | | 10.6 | | |
临床与法规事务
|
| | | | 23.2 | | | | | | 8.2 | | |
质量保证与监管
|
| | | | 7.9 | | | | | | 5.9 | | |
运营
|
| | | | 15 | | | | | | 9.0 | | |
治疗开发(包括销售团队)
|
| | | | 6 | | | | | | 2.0 | | |
总计
|
| | | | 71.9 | | | | | | 42.5 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
年初的净固定收益负债
|
| | | | 30 | | | | | | 13 | | |
计入损益的固定收益成本
|
| | | | 93 | | | | | | 90 | | |
保险业保单包括的总重量值
|
| | | | — | | | | | | — | | |
雇主供款
|
| | | | (77) | | | | | | (73) | | |
转移预留(终止参与者)
|
| | | | (9) | | | | | | — | | |
年底固定福利负债净额
|
| | | | 37 | | | | | | 30 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
年初的总固定收益负债
|
| | | | 209 | | | | | | 118 | | |
当前服务成本
|
| | | | 90 | | | | | | 90 | | |
利息成本
|
| | | | 1 | | | | | | 2 | | |
缴款税
|
| | | | (8) | | | | | | (1) | | |
转移预留(终止参与者)
|
| | | | (60) | | | | | | — | | |
因财务假设改变而造成的精算损失
|
| | | | 16 | | | | | | — | | |
年终总固定福利负债
|
| | | | 248 | | | | | | 209 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
年初公允价值计划资产
|
| | | | 179 | | | | | | 106 | | |
利息收入
|
| | | | 2 | | | | | | 1 | | |
雇主供款
|
| | | | 77 | | | | | | 73 | | |
缴款税
|
| | | | (8) | | | | | | (1) | | |
转移预留(终止参与者)
|
| | | | (55) | | | | | | — | | |
计划资产公允价值精算收益
|
| | | | 16 | | | | | | — | | |
年末公允价值计划资产
|
| | | | 211 | | | | | | 179 | | |
| | |
2020
|
| |
2019
|
| ||||||
活跃会员
|
| | | | 14 | | | | | | 8 | | |
非活动成员
|
| | | | — | | | | | | — | | |
平均年龄
|
| | | | 43 | | | | | | 48 | | |
| | |
2020
|
| |
2019
|
|
贴现率
|
| |
0.1%
|
| |
0.6%
|
|
通货膨胀率
|
| |
2%
|
| |
2%
|
|
加薪(超过通货膨胀)
|
| |
0%
|
| |
0%
|
|
基于年龄的提款率(之间)
|
| |
1.5%和8.50%
|
| |
1.5%和8.50%
|
|
(单位:000欧元)
|
| |
2020
|
| |||
贴现率提高0.25%
|
| | | | (2) | | |
贴现率降低0.25%
|
| | | | 2 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
利益
|
| | | | 3 | | | | | | 8 | | |
汇兑差额
|
| | | | 59 | | | | | | 63 | | |
财务总收入
|
| | | | 62 | | | | | | 71 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
可收回现金垫款、贴现
|
| | | | 772 | | | | | | 575 | | |
利息和银行手续费
|
| | | | 151 | | | | | | 33 | | |
租赁负债利息
|
| | | | 47 | | | | | | 17 | | |
汇兑差额
|
| | | | 20 | | | | | | 115 | | |
财务费用总额
|
| | | | 990 | | | | | | 740 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
当期税额
|
| | | | (104) | | | | | | (61) | | |
递延税项收入/(费用)
|
| | | | 11 | | | | | | (9) | | |
所得税费用总额
|
| | | | (93) | | | | | | (70) | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
税前账面收益/(亏损)
|
| | | | (12,152) | | | | | | (8,384) | | |
公司法定所得税税率
|
| | | | 25.00% | | | | | | 29.58% | | |
按公司法定税率征收的所得税:
|
| | | | 3,038 | | | | | | 2,480 | | |
关于税收损失和暂时性差异的未确认DTA
|
| | | | (2,681) | | | | | | (2,132) | | |
不可扣除的费用
|
| | | | (488) | | | | | | (426) | | |
国外税率差异
|
| | | | 58 | | | | | | 38 | | |
其他暂时性差异
|
| | | | (20) | | | | | | (30) | | |
按公司实际税率计算的所得税
|
| | | | (93) | | | | | | (70) | | |
公司有效所得税税率
|
| | | | (0.77)% | | | | | | (0.83)% | | |
| | |
2020
|
| |
2019
|
| ||||||
截至12月31日,在转换和股份拆分后 | | | | | | | | | | | | | |
年终已发行普通股
|
| | | | 22,097,609 | | | | | | 6,728,500 | | |
已发行普通股加权平均数
|
| | | | 18,097,988 | | | | | | 6,728,500 | | |
因行使已发行股份而产生的股份数目
认股权证 |
| | | | 1,007,500 | | | | | | 1,143,500 | | |
| | |
2020
|
| |
2019
|
| ||||||
普通股持有人应占年度亏损(欧元)
|
| | | | (12,245,000) | | | | | | (3,823,000) | | |
优先股持有人应占年度亏损(欧元)
|
| | | | 0 | | | | | | (4,631,000) | | |
股东应占年度亏损(欧元)
|
| | | | (12,245,000) | | | | | | (8,454,000) | | |
已发行普通股加权平均数
(单位:单位) |
| | | | 18,097,988 | | | | | | 6,728,500 | | |
以欧元计算的每股基本收益(欧元/单位)
|
| | | | (0.677) | | | | | | (0.568) | | |
稀释后每股收益(欧元/单位)
|
| | | | (0.677) | | | | | | (0.568) | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
费用
|
| | | | 89 | | | | | | 115 | | |
总计 | | | | | 89 | | | | | | 115 | | |
(单位:000欧元)
|
| |
2020
|
| |
2019
|
| ||||||
短期报酬和补偿
|
| | | | 337 | | | | | | 612 | | |
股份支付
|
| | | | 1,576 | | | | | | 231 | | |
总计 | | | | | 1,913 | | | | | | 843 | | |
| | |
12/31/2020
|
| |
12/31/2019
|
| ||||||||||||||||||||||||
(单位:000欧元)
|
| |
研发
协作 |
| |
咨询
服务 |
| |
冲浪板
报酬 |
| |
咨询
服务 |
| |
冲浪板
报酬 |
| |||||||||||||||
耳蜗
|
| | | | 1,300 | | | | | | — | | | | | | — | | | | | | 839 | | | | | | — | | |
诺沙克
|
| | | | — | | | | | | 10 | | | | | | — | | | | | | — | | | | | | — | | |
MINV SA
|
| | | | — | | | | | | 50 | | | | | | — | | | | | | 79 | | | | | | — | | |
“人与科学”(Man&Science S.A.)
|
| | | | — | | | | | | 44 | | | | | | — | | | | | | 6 | | | | | | — | | |
克里斯托弗·史密斯
|
| | | | — | | | | | | — | | | | | | — | | | | | | 9 | | | | | | 11 | | |
医疗技术高管有限责任公司
|
| | | | — | | | | | | — | | | | | | 9 | | | | | | — | | | | | | 31 | | |
罗伯特·陶布
|
| | | | — | | | | | | — | | | | | | 28 | | | | | | — | | | | | | — | | |
凯文·拉金
|
| | | | — | | | | | | — | | | | | | 8 | | | | | | — | | | | | | — | | |
唐纳德·德约
|
| | | | — | | | | | | — | | | | | | 12 | | | | | | — | | | | | | — | | |
皮埃尔·贾内洛
|
| | | | — | | | | | | — | | | | | | 8 | | | | | | — | | | | | | — | | |
扬·詹森(Jan Janssen)
|
| | | | — | | | | | | — | | | | | | 8 | | | | | | — | | | | | | — | | |
于尔根·汉布雷希特
|
| | | | — | | | | | | — | | | | | | 9 | | | | | | — | | | | | | — | | |
总计 | | | | | 1,300 | | | | | | 104 | | | | | | 90 | | | | | | 935 | | | | | | 42 | | |
| | |
截至3月31日
2021 |
| |
截至12月31日
2020 |
| ||||||
资产 | | | | | | | | | | | | | |
非流动资产 | | | | | | | | | | | | | |
财产、厂房和设备
|
| | | € | 852 | | | | | € | 713 | | |
无形资产
|
| | | | 17,247 | | | | | | 15,853 | | |
使用权资产
|
| | | | 3,158 | | | | | | 3,283 | | |
递延税项资产
|
| | | | 41 | | | | | | 32 | | |
其他长期应收账款
|
| | | | 91 | | | | | | 91 | | |
| | | | € | 21,389 | | | | | € | 19,972 | | |
流动资产 | | | | | | | | | | | | | |
库存
|
| | | | 106 | | | | | | 55 | | |
应收贸易账款
|
| | | | 185 | | | | | | | | |
其他应收账款
|
| | | | 1,699 | | | | | | 1,644 | | |
其他流动资产
|
| | | | 1,064 | | | | | | 109 | | |
现金和现金等价物
|
| | | | 86,207 | | | | | | 92,300 | | |
| | | | € | 89,261 | | | | | € | 94,108 | | |
总资产
|
| | | € | 110,650 | | | | | € | 114,080 | | |
权益和负债 | | | | | | | | | | | | | |
资本和储备 | | | | | | | | | | | | | |
普通股
|
| | | | 3,798 | | | | | | 3,796 | | |
股票溢价
|
| | | | 150,986 | | | | | | 150,936 | | |
股份支付准备金
|
| | | | 2,650 | | | | | | 2,650 | | |
货币换算储备
|
| | | | 79 | | | | | | 149 | | |
留存收益
|
| | | | (66,010) | | | | | | (60,341) | | |
股东应占权益总额
|
| | | € | 91,503 | | | | | € | 97,190 | | |
负债 | | | | | | | | | | | | | |
非流动负债 | | | | | | | | | | | | | |
金融债
|
| | | | 7,757 | | | | | | 7,607 | | |
租赁责任
|
| | | | 2,737 | | | | | | 2,844 | | |
养老金负债
|
| | | | 37 | | | | | | 37 | | |
| | | | € | 10,531 | | | | | € | 10,488 | | |
流动负债 | | | | | | | | | | | | | |
金融债
|
| | | | 658 | | | | | | 616 | | |
租赁责任
|
| | | | 475 | | | | | | 473 | | |
贸易应付款
|
| | | | 2,802 | | | | | | 1,190 | | |
其他应付款
|
| | | | 4,681 | | | | | | 4,123 | | |
| | | | € | 8,616 | | | | | € | 6,402 | | |
总负债
|
| | | € | 19,147 | | | | | € | 16,890 | | |
权益和负债总额
|
| | | € | 110,650 | | | | | € | 114,080 | | |
| | |
截至3月31日的三个月
|
| |||||||||
|
2021
|
| |
2020
|
| ||||||||
收入
|
| | | € | 185 | | | | | € | — | | |
销货成本
|
| | | | (52) | | | | | | — | | |
毛利
|
| | |
€
|
133
|
| | | | € | — | | |
一般和行政费用
|
| | | | (1,818) | | | | | | (1,178) | | |
研发费用
|
| | | | (852) | | | | | | (7) | | |
临床费用
|
| | | | (342) | | | | | | (177) | | |
制造费用
|
| | | | (901) | | | | | | (62) | | |
质量保证和监管费用
|
| | | | (325) | | | | | | (25) | | |
专利费及相关费用
|
| | | | (674) | | | | | | (58) | | |
治疗开发费用
|
| | | | (548) | | | | | | (352) | | |
其他营业收入/(费用)
|
| | | | 4 | | | | | | (191) | | |
当期营业亏损
|
| | |
€
|
(5,323)
|
| | | |
€
|
(2,050)
|
| |
财政收入
|
| | | | 4 | | | | | | 19 | | |
财务费用
|
| | | | (325) | | | | | | (336) | | |
税前亏损
|
| | | € | (5,644) | | | | | € | (2,367) | | |
所得税
|
| | | | (25) | | | | | | (13) | | |
当期亏损
|
| | | € | (5,669) | | | | | € | (2,380) | | |
其他综合损失 | | | | | | | | | | | | | |
可能随后重新分类为损益的项目
(税后净额) |
| | | | | | | | | | | | |
货币换算差异
|
| | | | (70) | | | | | | 272 | | |
本年度扣除税项后的综合亏损总额
|
| | | € | (5,739) | | | | | € | (2,108) | | |
股东应占亏损
|
| | | € | (5,739) | | | | | € | (2,108) | | |
每股基本亏损
|
| | | € | (0.256) | | | | | € | (0.151) | | |
稀释每股亏损
|
| | | € | (0.256) | | | | | € | (0.151) | | |
| | |
可归因于母公司的所有者
|
| |||||||||||||||||||||||||||||||||||||||
截至3月31日及截至3月31日的三个月, 2021 |
| |
普普通通
股票 |
| |
择优
股票 |
| |
分享
补价 |
| |
分享
基于 付款 保留 |
| |
货币
翻译 保留 |
| |
留用
收益 |
| |
总计
|
| |||||||||||||||||||||
2021年1月1日的余额
|
| | | € | 3,796 | | | | | | — | | | | | € | 150,936 | | | | | € | 2,650 | | | | | € | 149 | | | | | € | (60,341) | | | | | € | 97,190 | | |
当期亏损
|
| | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | | | (5,669) | | | | | | (5,669) | | |
当期其他全面亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (70) | | | | | | — | | | | | | (70) | | |
本期综合亏损总额
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | € | (70) | | | | | € | (5,669) | | | | | € | (5,739) | | |
发行股票换取现金
|
| | | | 2 | | | | | | — | | | | | | 50 | | | | | | — | | | | | | — | | | | | | — | | | | | | 52 | | |
与直接在股权中确认的公司所有者的交易总额
|
| | | € | 2 | | | | | | — | | | | | € | 50 | | | | | | — | | | | | | — | | | | | | — | | | | | € | 52 | | |
2021年3月31日的余额
|
| | | € | 3,798 | | | | | | — | | | | | € | 150,986 | | | | | € | 2,650 | | | | | € | 79 | | | | | € | (66,010) | | | | | € | 91,503 | | |
截至3月31日及截至3月31日的三个月, 2020 |
| |
普普通通
股票 |
| |
择优
股票 |
| |
分享
补价 |
| |
分享
基于 付款 保留 |
| |
货币
翻译 保留 |
| |
留用
收益 |
| |
总计
|
| |||||||||||||||||||||
2020年1月1日的余额
|
| | | € | 1,122 | | | | | € | 1,359 | | | | | € | 47,668 | | | | | € | 420 | | | | | € | 207 | | | | | € | (48,415) | | | | | € | 2,361 | | |
当期亏损
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (2,380) | | | | | | (2,380) | | |
期内其他全面收入
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 272 | | | | | | — | | | | | | 272 | | |
当期综合收益/(亏损)合计
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | € | 272 | | | | | € | (2,380) | | | | | € | (2,108) | | |
股权结算股份支付
|
| | | | — | | | | | | — | | | | | | — | | | | | | 147 | | | | | | — | | | | | | 50 | | | | | | 197 | | |
发行股票换取现金
|
| | | | 436 | | | | | | — | | | | | | 24,624 | | | | | | — | | | | | | — | | | | | | — | | | | | | 25,060 | | |
交易成本
|
| | | | — | | | | | | — | | | | | | (96) | | | | | | — | | | | | | — | | | | | | — | | | | | | (96) | | |
将优先股转换为普通股
|
| | | | 1,359 | | | | | | (1,359) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
与公司所有者的交易总额
直接在权益中确认 |
| | | € | 1,795 | | | | | | (1,359) | | | | | € | 24,528 | | | | | € | 147 | | | | | | — | | | | | € | 50 | | | | | € | 25,161 | | |
2020年3月31日的余额
|
| | | € | 2,917 | | | | | | — | | | | | € | 72,196 | | | | | € | 567 | | | | | € | 479 | | | | | € | (50,745) | | | | | € | 25,414 | | |
| | |
截至3月31日的三个月
|
| |||||||||
|
2021
|
| |
2020
|
| ||||||||
经营活动的现金流 | | | | | | | | | | | | | |
本期税前亏损
|
| | | € | (5,644) | | | | | € | (2,367) | | |
对以下各项进行调整: | | | | | | | | | | | | | |
财政收入
|
| | | | (4) | | | | | | (19) | | |
财务费用
|
| | | | 325 | | | | | | 336 | | |
财产、厂房和设备以及使用权资产的折旧和减值
|
| | | | 375 | | | | | | 128 | | |
股份支付交易费用
|
| | | | — | | | | | | 197 | | |
其他非现金项目
|
| | | | 3 | | | | | | 111 | | |
营运资金变动前使用的现金
|
| | | € | (4,945) | | | | | € | (1,614) | | |
营运资金变动: | | | | | | | | | | | | | |
库存增加
|
| | | | (51) | | | | | | — | | |
贸易应收账款增加
|
| | | | (185) | | | | | | — | | |
其他应收账款减少/(增加)
|
| | | | (1,010) | | | | | | 402 | | |
贸易和其他应付款项的增加
|
| | | | 2,170 | | | | | | 35 | | |
用于运营变更的现金
|
| | | € | (4,021) | | | | | € | (1,177) | | |
收到的利息
|
| | | | 1 | | | | | | 2 | | |
支付的利息
|
| | | | (105) | | | | | | (5) | | |
已缴所得税
|
| | | | (34) | | | | | | (17) | | |
用于经营活动的现金净额
|
| | | € | (4,159) | | | | | € | (1,197) | | |
用于投资活动的现金流 | | | | | | | | | | | | | |
购置物业、厂房及设备
|
| | | | (169) | | | | | | (84) | | |
无形资产资本化
|
| | | | (1,606) | | | | | | (1,694) | | |
增加长期存款
|
| | | | — | | | | | | 1 | | |
用于投资活动的净现金
|
| | | € | (1,775) | | | | | € | (1,777) | | |
用于融资活动/产生于融资活动的现金流
|
| | | | | | | | | | | | |
支付租赁负债的本金部分
|
| | | | (135) | | | | | | (105) | | |
偿还其他贷款
|
| | | | (21) | | | | | | (21) | | |
股票发行收益,扣除交易成本
|
| | | | 52 | | | | | | 24,964 | | |
融资活动中使用/产生的净现金
|
| | | € | (104) | | | | | € | 24,838 | | |
现金和现金等价物的变动
|
| | | € | (6,038) | | | | | € | 21,864 | | |
汇率对现金和现金等价物的影响
|
| | | | (55) | | | | | | 155 | | |
1月1日的现金和现金等价物
|
| | | € | 92,300 | | | | | € | 5,855 | | |
3月31日的现金和现金等价物
|
| | | € | 86,207 | | | | | € | 27,874 | | |
| | |
账面价值
|
| |
公允价值
|
| ||||||||||||||||||
(单位:000欧元)
|
| |
截至
3月31日, 2021 |
| |
截至
12月31日, 2020 |
| |
截至
3月31日, 2021 |
| |
截至
12月31日, 2020 |
| ||||||||||||
金融资产 | | | | | | | | | | | | | | | | | | | | | | | | | |
其他长期应收账款(三级)
|
| | | | 91 | | | | | | 91 | | | | | | 91 | | | | | | 91 | | |
贸易应收账款和其他应收账款(第3级)
|
| | | | 1,884 | | | | | | 1,644 | | | | | | 1,884 | | | | | | 1,644 | | |
其他流动资产(3级)
|
| | | | 1,064 | | | | | | 109 | | | | | | 1,064 | | | | | | 109 | | |
现金和现金等价物(一级)
|
| | | | 86,207 | | | | | | 92,300 | | | | | | 86,207 | | | | | | 92,300 | | |
金融负债 | | | | | | | | | | | | | | | | | | | | | | | | | |
金融债务(三级)
|
| | | | 292 | | | | | | 313 | | | | | | 268 | | | | | | 250 | | |
可收回现金垫款(3级)
|
| | | | 8,123 | | | | | | 7,910 | | | | | | 8,123 | | | | | | 7,910 | | |
贸易和其他应付款(第3层)
|
| | | | 7,484 | | | | | | 5,313 | | | | | | 7,484 | | | | | | 5,313 | | |
(单位:000欧元)
|
| |
发展
成本 |
| |
专利和许可证
|
| |
总计
|
| |||||||||
成本 | | | | | |||||||||||||||
2020年1月1日的期初总值
|
| | | | 5,311 | | | | | | 335 | | | | | | 5,646 | | |
加法
|
| | | | 1,653 | | | | | | 56 | | | | | | 1,709 | | |
2020年3月31日的毛值
|
| | | | 6,964 | | | | | | 391 | | | | | | 7,355 | | |
2021年1月1日的期初毛值
|
| | | | 15,185 | | | | | | 591 | | | | | | 15,776 | | |
加法
|
| | | | 1,598 | | | | | | — | | | | | | 1,598 | | |
2021年3月31日的毛值
|
| | | | 16,783 | | | | | | 591 | | | | | | 17,374 | | |
摊销 | | | | | | | | | | | | | | | | | | | |
期初摊销于2020年1月1日
|
| | | | — | | | | | | — | | | | | | — | | |
摊销
|
| | | | — | | | | | | — | | | | | | — | | |
于2020年3月31日摊销
|
| | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| |
期初摊销于2021年1月1日
|
| | | | — | | | | | | — | | | | | | — | | |
摊销
|
| | | | (211) | | | | | | — | | | | | | (211) | | |
于2021年3月31日摊销
|
| | | | (211) | | | | | | — | | | | | | (211) | | |
2020年1月1日的开盘汇差
|
| | | | 88 | | | | | | — | | | | | | 88 | | |
汇兑差额
|
| | | | (15) | | | | | | — | | | | | | (15) | | |
2020年3月31日汇兑差额
|
| | | | 73 | | | | |
|
—
|
| | | | | 73 | | |
2021年1月1日的开盘汇差
|
| | |
|
77
|
| | | | | — | | | | |
|
77
|
| |
汇兑差额
|
| | | | 7 | | | | | | — | | | | | | 7 | | |
2021年3月31日汇兑差额
|
| | | | 84 | | | | |
|
—
|
| | | | | 84 | | |
2020年3月31日的账面净值
|
| | | | 6,037 | | | | | | 391 | | | | | | 7,428 | | |
2021年3月31日的账面净值
|
| | | | 16,656 | | | | | | 591 | | | | | | 17,247 | | |
(单位:000欧元)
|
| |
截至3月31日,
2021 |
| |
截至2013年12月31日,
2020 |
| ||||||
研发奖励应收账款(澳大利亚)
|
| | | | 1,222 | | | | | | 951 | | |
增值税应收账款
|
| | | | 398 | | | | | | 607 | | |
当期应收税金
|
| | | | 28 | | | | | | (3) | | |
其他
|
| | | | 51 | | | | | | 89 | | |
其他应收账款合计
|
| | | | 1,699 | | | | | | 1,644 | | |
(单位:000欧元)
|
| |
截止到三月三十一号,
2021 |
| |
截止到十二月三十一号,
2020 |
| ||||||
预付交易成本
|
| | | | 915 | | | | | | — | | |
其他预付费
|
| | | | 149 | | | | | | 109 | | |
其他流动资产总额
|
| | | | 1,064 | | | | | | 109 | | |
(单位:000欧元)
|
| |
截至3月31日,
2021 |
| |
截至2013年12月31日,
2020 |
| ||||||
短期存款
|
| | | | 28 | | | | | | 28 | | |
三个月定期存款
|
| | | | 6 | | | | | | 6 | | |
经常账户
|
| | | | 86,173 | | | | | | 92,266 | | |
现金和现金等价物合计
|
| | |
|
86,207
|
| | | | | 92,300 | | |
(股份数目(1),除非另有规定 述明) |
| |
普普通通
股票 |
| |
择优
股票 |
| |
总计
股票 |
| |
面值
(欧元) |
| |
分享
资本 |
| |
分享
补价 |
| ||||||||||||||||||
2020年1月1日(根据2020年的股票拆分进行调整)
|
| | |
|
6,728,500
|
| | | |
|
8,150,000
|
| | | |
|
14,879,000
|
| | | |
|
0.17
|
| | | |
|
2,481
|
| | | |
|
47,668
|
| |
2020年2月21日 - 转换
优先股转换为普通股 股票 |
| | | | 8,150,000 | | | | | | (8,150,000) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
2020年2月21日 - 增资
|
| | | | 2,100,000 | | | | | | — | | | | | | 2,100,000 | | | | | | 0.21 | | | | | | 436 | | | | | | 24,624 | | |
2020年3月31日(根据2020年股票拆分进行调整)
|
| | | | 16,979,000 | | | | | | — | | | | | | 22,097,609 | | | | | | 0.17 | | | | | | 3,796 | | | | | | 157,514 | | |
2020年9月7日 - 行权证
|
| | | | 44,500 | | | | | | | | | | | | 44,500 | | | | | | 0,17 | | | | | | 8 | | | | | | 222 | | |
2020年9月21日 - 首次公开募股
|
| | | | 4,335,000 | | | | | | — | | | | | | 4,335,000 | | | | | | 0.17 | | | | | | 745 | | | | | | 72,950 | | |
2020年9月21日 - 可转换贷款
|
| | | | 65,359 | | | | | | — | | | | | | 65,359 | | | | | | 0.17 | | | | | | 11 | | | | | | 989 | | |
2020年9月29日 - 行权证
|
| | | | 650,250 | | | | | | — | | | | | | 650,250 | | | | | | 0.17 | | | | | | 112 | | | | | | 10,943 | | |
2020年10月28日 - 行权证
|
| | | | 23,500 | | | | | | — | | | | | | 23,500 | | | | | | 0.17 | | | | | | 4 | | | | | | 117 | | |
2020年12月31日(根据2020年股票拆分进行调整)
|
| | |
|
22,097,609
|
| | | |
|
—
|
| | | |
|
22,097,609
|
| | | |
|
0.17
|
| | | |
|
3,796
|
| | | |
|
157,514
|
| |
2021年2月22日 - 增资
|
| | | | 10,000 | | | | | | — | | | | | | 10,000 | | | | | | 0.17 | | | | | | 2 | | | | | | 50 | | |
2021年3月31日(根据2020年的股票拆分进行调整)
|
| | | | 22,107,609 | | | | | | — | | | | | | 22,107,609 | | | | | | 0.17 | | | | | | 3,798 | | | | | | 157,564 | | |
(单位:000欧元)
|
| |
截至2021年3月31日
|
| |
截至2020年12月31日
|
| ||||||
可回收现金预付款 - 非流动
|
| | | | 7,590 | | | | | | 7,149 | | |
可回收现金预付款 - Current
|
| | | | 533 | | | | | | 491 | | |
可收回现金预付款总额
|
| | | | 8,123 | | | | | | 7,910 | | |
其他非流动贷款 -
|
| | | | 167 | | | | | | 188 | | |
其他贷款 - 流动
|
| | | | 125 | | | | | | 125 | | |
其他贷款总额
|
| | | | 292 | | | | | | 313 | | |
非电流
|
| | | | 7,757 | | | | | | 7,607 | | |
当前
|
| | | | 658 | | | | | | 616 | | |
金融债务总额
|
| | | | 8,415 | | | | | | 8,223 | | |
(单位:000欧元)
|
| |
合同
预支款 |
| |
预支款
收到 |
| |
金额
已报销 |
| |||||||||
睡眠呼吸暂停设备(6472)
|
| | | | 1,600 | | | | | | 1,600 | | | | | | 420 | | |
第一篇文章(6839)
|
| | | | 2,160 | | | | | | 2,160 | | | | | | 84 | | |
临床试验(6840)
|
| | | | 2,400 | | | | | | 2,400 | | | | |
|
—
|
| |
激活芯片改进(7388)
|
| | | | 1,467 | | | | | | 1,467 | | | | | | 15 | | |
总计 | | | | | 7,627 | | | | | | 7,627 | | | | | | 519 | | |
(单位:000欧元)
|
| |
截至3月31日,
2021 |
| |
截至2013年12月31日,
2020 |
| ||||||
合同6472
|
| | | | 1,464 | | | | | | 1,421 | | |
合约6839
|
| | | | 2,272 | | | | | | 2,214 | | |
合约6840
|
| | | | 2,659 | | | | | | 2,592 | | |
合约7388
|
| | | | 1,728 | | | | | | 1,683 | | |
可收回现金预付款总额
|
| | | | 8,123 | | | | | | 7,910 | | |
非电流
|
| | | | 7,590 | | | | | | 7,419 | | |
当前
|
| | | | 533 | | | | | | 491 | | |
可收回现金预付款总额
|
| | | | 8,123 | | | | | | 7,910 | | |
(单位:000欧元)
|
| |
2021
|
| |
2020
|
| ||||||
截至1月1日
|
| | | | 7,910 | | | | | | 7,148 | | |
初始测量和重新测量
|
| | | | (8) | | | | | | 100 | | |
贴现影响
|
| | | | 220 | | | | | | 193 | | |
截至2021年3月31日
|
| | | | 8,123 | | | | | | 7,442 | | |
(单位:000欧元)
|
| |
截至3月31日,
2021 |
| |
截至2013年12月31日,
2020 |
| ||||||
假日应计工资
|
| | | | 486 | | | | | | 376 | | |
薪金
|
| | | | 355 | | | | | | 382 | | |
应计费用
|
| | | | 1,070 | | | | | | 1,244 | | |
其他
|
| | | | 2,769 | | | | | | 2,121 | | |
其他应付款合计
|
| | | | 4,680 | | | | | | 4,123 | | |
(单位:000欧元)
|
| |
2021
|
| |
2020
|
| ||||||
购买商品和服务
|
| | | | 103 | | | | | | — | | |
库存移动
|
| | | | (51) | | | | | | — | | |
商品销售总成本
|
| | | | 52 | | | | | | — | | |
(单位:000欧元)
|
| |
总成本
|
| |
大写
|
| |
运营费用
在这段期间内 |
| |||||||||
一般和行政费用
|
| | | | 1,818 | | | | | | — | | | | | | 1,818 | | |
研发费用
|
| | | | 852 | | | | | | — | | | | | | 852 | | |
临床费用
|
| | | | 1,779 | | | | | | (1,437) | | | | | | 342 | | |
制造费用
|
| | | | 1,116 | | | | | | (215) | | | | | | 901 | | |
质量保证和监管费用
|
| | | | 458 | | | | | | (133) | | | | | | 325 | | |
专利费及相关费用
|
| | | | 674 | | | | | | — | | | | | | 674 | | |
治疗开发费用
|
| | | | 548 | | | | | | — | | | | | | 548 | | |
其他营业费用/(收入)
|
| | | | (191) | | | | | | 187 | | | | | | (4) | | |
截至2021年3月31日的三个月
|
| | | | 7,054 | | | | | | (1,598) | | | | | | 5,456 | | |
(单位:000欧元)
|
| |
总成本
|
| |
大写
|
| |
运营费用
在这段期间内 |
| |||||||||
一般和行政费用
|
| | | | 1,178 | | | | | | — | | | | | | 1,178 | | |
研发费用
|
| | | | 318 | | | | | | (311) | | | | | | 7 | | |
临床费用
|
| | | | 745 | | | | | | (568) | | | | | | 177 | | |
制造费用
|
| | | | 640 | | | | | | (578) | | | | | | 62 | | |
质量保证和监管费用
|
| | | | 288 | | | | | | (263) | | | | | | 25 | | |
专利费及相关费用
|
| | | | 114 | | | | | | (56) | | | | | | 58 | | |
治疗开发费用
|
| | | | 352 | | | | | | — | | | | | | 352 | | |
其他营业费用/(收入)
|
| | | | 124 | | | | | | 67 | | | | | | 191 | | |
截至2020年3月31日的三个月
|
| | | | 3,759 | | | | | | (1,709) | | | | | | 2,050 | | |
(单位:000欧元)
|
| |
三个月的时间
期间已结束 2021年3月31日 |
| |
三个月的时间
期间已结束 2020年3月31日 |
| ||||||
员工成本
|
| | | | 366 | | | | | | 426 | | |
咨询费和承包费
|
| | | | 936 | | | | | | 431 | | |
律师费
|
| | | | 53 | | | | | | 22 | | |
租金
|
| | | | 61 | | | | | | 36 | | |
设施
|
| | | | 24 | | | | | | 21 | | |
折旧及摊销费用
|
| | | | 161 | | | | | | 124 | | |
信通技术
|
| | | | 112 | | | | | | 26 | | |
旅行
|
| | | | 25 | | | | | | 56 | | |
其他费用
|
| | | | 80 | | | | | | 36 | | |
一般和行政费用总额
|
| | |
|
1,818
|
| | | |
|
1,178
|
| |
(单位:000欧元)
|
| |
三个月的时间
期间已结束 2021年3月31日 |
| |
三个月的时间
期间已结束 2020年3月31日 |
| ||||||
员工成本
|
| | | | 414 | | | | | | 273 | | |
外包开发项目
|
| | | | 238 | | | | | | 39 | | |
折旧及摊销费用
|
| | | | 184 | | | | | | 3 | | |
旅行
|
| | | | — | | | | | | 3 | | |
其他
|
| | | | 16 | | | | | | — | | |
资本化成本
|
| | | | — | | | | | | (311) | | |
研发费用总额
|
| | | | 852 | | | | | | 7 | | |
(单位:000欧元)
|
| |
三个月的时间
期间已结束 2021年3月31日 |
| |
三个月的时间
期间已结束 2020年3月31日 |
| ||||||
员工成本
|
| | | | 313 | | | | | | 179 | | |
咨询费和承包费
|
| | | | — | | | | | | — | | |
制造业
|
| | | | 793 | | | | | | 404 | | |
旅行
|
| | | | — | | | | | | 23 | | |
其他
|
| | | | 10 | | | | | | 34 | | |
资本化成本
|
| | | | (215) | | | | | | (578) | | |
总制造费用
|
| | | | 901 | | | | | | 62 | | |
| | |
2021
|
| |
2020
|
| ||||||
截至3月31日,在转换和股份拆分后 | | | | | | | | | | | | | |
年终已发行普通股
|
| | | | 22,107,609 | | | | | | 16,979,000 | | |
已发行普通股加权平均数
|
| | | | 22,101,766 | | | | | | 15,789,000 | | |
因行使已发行认股权证而产生的股份数目
|
| | | | 997,500 | | | | | | 1,007,500 | | |
| | |
2021
|
| |
2020
|
| ||||||
股东应占年度亏损(欧元)
|
| | | | (5,669,000) | | | | | | (2,380,000) | | |
已发行普通股加权平均数(单位:单位)
|
| | | | 22,101,766 | | | | | | 15,789,000 | | |
以欧元计算的每股基本收益(欧元/单位)
|
| | |
|
(0.256)
|
| | | |
|
(0.151)
|
| |
稀释后每股收益(欧元/单位)
|
| | | | (0.256) | | | | | | (0.151) | | |
(单位:000欧元)
|
| |
2021
|
| |
2020
|
| ||||||
短期报酬和补偿
|
| | | | 69 | | | | | | 61 | | |
股份支付
|
| | | | — | | | | | | — | | |
总计 | | | | | 69 | | | | | | 61 | | |
| | |
截至2021年3月31日
|
| |
截至2020年3月31日
|
| ||||||||||||||||||||||||
(单位:000欧元)
|
| |
研发
协作 |
| |
咨询
服务 |
| |
冲浪板
报酬 |
| |
咨询
服务 |
| |
冲浪板
报酬 |
| |||||||||||||||
耳蜗
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
诺沙克 | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
MINV SA
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
“人与科学”(Man&Science S.A.)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
医疗技术高管有限责任公司
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3 | | |
唐纳德·德约
|
| | | | — | | | | | | — | | | | | | 11 | | | | | | — | | | | | | — | | |
罗伯特·陶布
|
| | | | — | | | | | | — | | | | | | 13 | | | | | | — | | | | | | — | | |
凯文·拉金
|
| | | | — | | | | | | — | | | | | | 8 | | | | | | — | | | | | | — | | |
皮埃尔·贾内洛
|
| | | | — | | | | | | — | | | | | | 7 | | | | | | — | | | | | | — | | |
扬·詹森(Jan Janssen)
|
| | | | — | | | | | | — | | | | | | 7 | | | | | | — | | | | | | — | | |
于尔根·汉布雷希特
|
| | | | — | | | | | | — | | | | | | 8 | | | | | | — | | | | | | — | | |
总计
|
| | | | — | | | | | | — | | | | | | 54 | | | | | | — | | | | | | 3 | | |
|
派珀·桑德勒
|
| |
斯蒂费尔
|
| |
康托尔
|
|
| | |
Degroof Petercam
|
| | |
陈列品 数 |
| |
展品说明
|
|
1.1* | | | 承销协议的格式 | |
3.1** | | | Nyxoah SA公司章程(英文译本) | |
5.1* | | | NautaDutilh BV/SRL的意见 | |
10.1# | | | 注册人和Cochlear Limited之间于2018年11月签署的Cochlear Collaboration协议 | |
10.2# | | | 由注册人和Adi Mashiach博士、Cephalix SA、Glucobel SA、Surgical Electronics SA和Man&Science SA签署并由注册人与Adi Mashiach博士、Cephalix SA、Glucobel SA、Surgical Electronics SA和Man&Science SA签订的许可协议,经注册人与Cephalix SA、Surgical Electronics SA和Man&Science SA之间于2016年6月23日签署的多方协议的确认性附录修订,并经日期为2月10日的多方协议确认性附录的澄清进一步修订。 | |
10.3* | | | 授权书(英文译本) | |
10.4# | | | 无保护租赁合同,日期为2020年8月20日,由Nyxoah Ltd和Block 7093 Parcel 162 Ltd之间签订(英文翻译) | |
21.1** | | | 注册人的子公司名单 | |
23.1* | | | 安永会计师事务所/安永Bedrijfsrevisoren SRL/BV,独立注册会计师事务所同意 | |
23.2* | | | NautaDutilh BV/SRL同意(包括在附件5.1中) | |
24.1* | | | 授权书(包括在本登记声明的签字页上) | |
|
签名
|
| |
标题
|
| |
日期
|
|
|
奥利维尔·塔尔曼(Olivier Taelman)
|
| |
首席执行官兼执行董事
(首席行政主任) |
| |
, 2021
|
|
|
费边·苏亚雷斯·冈萨雷斯(Fabian Suarez Gonzalez),ActuaRisk Consulting SRL代理
|
| |
首席财务官
(首席财务会计官) |
| |
, 2021
|
|
|
罗伯特·陶布
|
| |
董事会主席
|
| |
, 2021
|
|
|
扬克·迪特默(Janke Dittmer)
|
| |
董事会副主席
|
| |
, 2021
|
|
|
凯文·拉金
|
| |
导演
|
| |
, 2021
|
|
|
唐纳德·德约
|
| |
导演
|
| |
, 2021
|
|
|
签名
|
| |
标题
|
| |
日期
|
|
|
皮埃尔·贾内洛
|
| |
导演
|
| |
, 2021
|
|
|
扬·詹森(Jan Janssen)
|
| |
导演
|
| |
, 2021
|
|
|
于尔根·汉布雷希特
|
| |
导演
|
| |
, 2021
|
|